-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 WpgDuY5IqRsdZ5VXwVLlhnmFWQtqqG17K0Tpjv2ooo8GY9l1E+2DxIGDMDiVEQ4O
 FxCDjl4sEpCFDTLNpcfdrQ==

<SEC-DOCUMENT>0000950123-09-069658.txt : 20091210
<SEC-HEADER>0000950123-09-069658.hdr.sgml : 20091210
<ACCEPTANCE-DATETIME>20091210060223
ACCESSION NUMBER:		0000950123-09-069658
CONFORMED SUBMISSION TYPE:	F-1/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20091210
DATE AS OF CHANGE:		20091210

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Concord Medical Services Holdings Ltd
		CENTRAL INDEX KEY:			0001472072
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9

	FILING VALUES:
		FORM TYPE:		F-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-163155
		FILM NUMBER:		091232168

	BUSINESS ADDRESS:	
		STREET 1:		ROOM 2001-2002, 20TH FLOOR, TOWER A
		STREET 2:		GLOBAL TRADE CTR, 36 NORTH THIRD RING RD
		CITY:			DONGCHENG DISTRICT, BEIJING
		STATE:			F4
		ZIP:			100013
		BUSINESS PHONE:		(86)10-5825-6867

	MAIL ADDRESS:	
		STREET 1:		ROOM 2001-2002, 20TH FLOOR, TOWER A
		STREET 2:		GLOBAL TRADE CTR, 36 NORTH THIRD RING RD
		CITY:			DONGCHENG DISTRICT, BEIJING
		STATE:			F4
		ZIP:			100013
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1/A
<SEQUENCE>1
<FILENAME>h03611a5fv1za.htm
<DESCRIPTION>F-1/A
<TEXT>
<HTML>
<HEAD>
<TITLE>F-1/A</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 94%; margin-left: 3%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">As filed
    with the Securities and Exchange Commission on December&#160;10,
    2009</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B> Registration No.&#160;333-163155</B>
</DIV>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 2pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 14pt">SECURITIES AND EXCHANGE
    COMMISSION</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">Washington,&#160;D.C.
    20549</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Amendment No.&#160;5 to</B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 18pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times"><FONT style="white-space: nowrap">Form&#160;F-1</FONT><BR>
    <BR>
    <FONT style="font-size: 12pt">REGISTRATION STATEMENT<BR>
    UNDER<BR>
    THE SECURITIES ACT OF 1933</FONT></FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 24pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Concord
    Medical Services Holdings Limited</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Exact name of registrant as
    specified in its charter)</FONT></I>
</DIV>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Not Applicable</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Translation of
    registrant&#146;s name into English)</FONT></I>
</DIV>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="35%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="31%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="31%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="center" valign="top">
    <B>Cayman Islands</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <B>8011</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <B>Not Applicable</B>
</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(State or other jurisdiction
    of<BR>
    incorporation or organization)</FONT></I>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(Primary Standard Industrial<BR>
    Classification Code Number)</FONT></I>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(I.R.S. Employer<BR>
    Identification Number) </FONT></I>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>18/F, Tower A, Global Trade Center</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>36 North Third Ring Road East, Dongcheng District</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Beijing 100013</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>People&#146;s Republic of China</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>(86 10)&#160;5903-6688</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Address, including zip code,
    and telephone number, including area code, of registrant&#146;s
    principal executive offices)</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>National Registered Agents, Inc.</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>875 Avenue of the Americas, Suite&#160;501</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>New York, New York 10001</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="white-space: nowrap">(888)&#160;336-3926</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Name, address, including zip
    code, and telephone number, including area code, of agent for
    service)</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Copies to:</I></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="49%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="center" valign="top">
    <B>Leiming Chen</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <B>Portia Ku</B>
</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">
    <B>Simpson Thacher&#160;&#038; Bartlett LLP</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <B>O&#146;Melveny &#038; Myers LLP</B>
</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">
    <B>35th&#160;Floor, ICBC Tower</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <B>37/F Plaza 66, 1266 Nanjing Road W</B>
</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">
    <B>3 Garden Road</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <B>Shanghai, People&#146;s Republic of China</B>
</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">
    <B>Central, Hong Kong</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <B>(86&#160;21) 2307-7000</B>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="center" valign="top">
    <B><FONT style="white-space: nowrap">(852)&#160;2514-7600</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Approximate date of commencement of proposed sale to the
    public: </B>As soon as practicable after the effective date of
    this registration statement
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If any of the securities being registered on this form are to be
    offered on a delayed or continuous basis pursuant to
    Rule&#160;415 under the Securities Act of 1933, check the
    following
    box.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is filed to register additional securities for an
    offering pursuant to Rule&#160;462(b) under the Securities Act,
    check the following box and list the Securities Act registration
    statement number of the earlier effective registration statement
    for the same
    offering.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;<U>&#160;&#160;</U>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is a post-effective amendment filed pursuant to
    Rule&#160;462(c) under the Securities Act, check the following
    box and list the Securities Act registration statement number of
    the earlier effective registration statement for the same
    offering.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;<U>&#160;&#160;</U>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is a post-effective amendment filed pursuant to
    Rule&#160;462(d) under the Securities Act, check the following
    box and list the Securities Act registration statement number of
    the earliest effective registration statement for the same
    offering.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;<U>&#160;&#160;</U>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>The Registrant hereby amends this Registration Statement on
    such date or dates as may be necessary to delay its effective
    date until the Registrant shall file a further amendment which
    specifically states that this Registration Statement shall
    thereafter become effective in accordance with Section&#160;8(a)
    of the Securities Act of 1933, as amended or until the
    Registration Statement shall become effective on such date as
    the Securities and Exchange Commission, acting pursuant to such
    Section&#160;8(a), may determine.</B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 2pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->
<!-- XBRL Pagebreak Begin -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Explanatory
    Note</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The sole purpose of this amendment is to amend the exhibit index
    and to file Exhibit&#160;1.1 to the registration statement. No
    other changes have been made to the registration statement.
    Accordingly, this amendment consists only of the facing page,
    this explanatory note and Part&#160;II of the registration
    statement.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<!-- XBRL Pagebreak Begin -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PART&#160;II</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">INFORMATION
    NOT REQUIRED IN PROSPECTUS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ITEM&#160;6&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">INDEMNIFICATION
    OF DIRECTORS AND OFFICERS</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cayman Islands law does not limit the extent to which a
    company&#146;s articles of association may provide for
    indemnification of officers and directors, except to the extent
    any such provision may be held by the Cayman Islands courts to
    be contrary to public policy, such as to provide indemnification
    against civil fraud or the consequences of committing a crime.
    Our third amended and restated memorandum and articles of
    association, which will become effective upon the closing of
    this offering, will provide for indemnification of officers and
    directors for losses, damages, costs and expenses incurred in
    their capacities as such, except through their own dishonesty,
    fraud or default.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the form of indemnification agreements filed as
    Exhibit&#160;10.2 to this registration statement, we will agree
    to indemnify our directors and executive officers against
    certain liabilities and expenses incurred by such persons in
    connection with claims made by reason of their being such a
    director or executive officer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The form of underwriting agreement to be filed as
    Exhibit&#160;1.1 to this registration statement will also
    provide for indemnification of us and our officers and directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Insofar as indemnification for liabilities arising under the
    Securities Act may be permitted to directors, officers or
    persons controlling us under the foregoing provisions, we have
    been informed that in the opinion of the SEC such
    indemnification is against public policy as expressed in the
    Securities Act and is therefore unenforceable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ITEM&#160;7&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">RECENT
    SALES OF UNREGISTERED SECURITIES</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During the past three years, we have issued the following
    securities (including options to acquire our ordinary shares).
    We believe that each of the following issuances was exempt from
    registration under the Securities Act in reliance on
    Regulation&#160;S under the Securities Act or under
    Section&#160;4(2) of the Securities Act regarding transactions
    not involving a public offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="33%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="13%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="24%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="12%">&nbsp;</TD>	<!-- colindex=05 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Underwriting<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Date of Sale or<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="right" valign="bottom">
    <B>Consideration in<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Discount and<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Purchaser</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Issuance</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Number of Securities</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="right" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">U.S. dollars</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Commission</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Certain director of the registrant
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    November&#160;27,&#160;2007
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    1 ordinary share*
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.05
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Notable Enterprise Limited
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    March 8, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    225,000 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Dragon Image Investment Ltd.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    March 8, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    37,500 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>*

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    375
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Daketala International Investment Holdings Ltd.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    March 8, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    37,500 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>*

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    375
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Certain directors of the registrant and other minority
    shareholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    March 8, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    199,999 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>*

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,999.99
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Carlyle Asia Growth Partners III, L.P.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    April 3, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    53,292 Series A contingently redeemable convertible preferred
    shares<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,808,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    CAGP III Co-Investment, L.P.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    April 3, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    2,125 Series A contingently redeemable convertible preferred
    shares<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    191,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    CICC Sun Company Limited
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    April 3, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    26,535 Series A contingently redeemable convertible preferred
    shares
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Carlyle Asia Growth Partners III, L.P.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    April 10, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    convertible loan promissory
    note<SUP style="font-size: 85%; vertical-align: top">(3)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    19,233,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    CAGP III Co-Investment, L.P.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    April 10, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    convertible loan promissory
    note<SUP style="font-size: 85%; vertical-align: top">(4)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    767,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    CZY Investments Limited
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    August 18, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    109,736 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(5)</SUP>*

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,669,144
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Daketala International Investment Holdings Ltd.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    August 18, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    47,030 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(5)</SUP>*

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,715,370
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Thousand Ocean Group Limited
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    August 18, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    32,624 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(5)</SUP>*

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,577,296
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Dragon Image Investment Ltd.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    August 18, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    16,524 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(5)</SUP>*

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,305,396
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Top Mount Group Limited
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    August 18, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    5,932 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(5)</SUP>*

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    468,628
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->


<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="33%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="13%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="24%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="12%">&nbsp;</TD>	<!-- colindex=05 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Underwriting<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Date of Sale or<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="right" valign="bottom">
    <B>Consideration in<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Discount and<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Purchaser</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Issuance</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Number of Securities</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="right" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">U.S. dollars</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Commission</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Carlyle Asia Growth Partners III, L.P.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    October 20, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    93,493 Series B contingently redeemable convertible preferred
    shares
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    24,041,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    CAGP III Co-Investment, L.P.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    October 20, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    3,728 Series B contingently redeemable convertible preferred
    shares
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    958,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    CICC Sun Company Limited
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    October 20, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    38,889 Series B contingently redeemable convertible preferred
    shares
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Starr Investments Cayman II, Inc.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    October 20, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    97,222 Series B contingently redeemable convertible preferred
    shares
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Directors, Officers and Employees of the Registrant
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    November&#160;27, 2009
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    Option to purchase 4,765,800 ordinary shares
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Nil
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>


<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Issued in connection with a share
    swap with Ascendium Group Limited as part of the reorganization
    to establish Concord Medical Services Holdings Limited as our
    ultimate holding company.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The numbers of Series&#160;A
    contingently redeemable convertible preferred shares issued to
    Carlyle Asia Growth Partners III, L.P. and CAGP III
    Co-Investment, L.P. on April&#160;3, 2008 also include
    Series&#160;A contingently redeemable convertible preferred
    shares issued as a result of the conversion of two convertible
    loan promissory notes issued on November&#160;16, 2007 by our
    predecessor, Our Medical Services, Ltd., or OMS, plus accrued
    interest. OMS received consideration for the issuance of such
    convertible loan promissory notes in the amount of $4,808,250
    and $191,750 from Carlyle Asia Growth Partners III, L.P. and
    CAGP III Co-Investment, L.P., respectively.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The convertible loan promissory
    note was converted into 84,072 of our Series&#160;A contingently
    redeemable convertible preferred shares on July&#160;30, 2008.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The convertible loan promissory
    note was converted into 3,353 of our Series&#160;A contingently
    redeemable convertible preferred shares on July&#160;30, 2008.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(5)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Issued as settlement for the share
    options issued to certain of our directors under the share
    option plan adopted by our predecessor company, Our Medical
    Services Limited, on November&#160;17, 2007.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">*
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Does not take into account the
    share split effective on November&#160;17, 2009 whereby all of
    our issued and outstanding 704,281 ordinary shares of a par
    value of US$0.01 per share were split into 70,428,100 ordinary
    shares of US$0.0001 par value per share and the number of our
    authorized ordinary shares was increased from 4,500,000 to
    450,000,000.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ITEM&#160;8&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">EXHIBITS&#160;AND
    FINANCIAL STATEMENT SCHEDULES</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See Exhibit&#160;Index beginning on
    <FONT style="white-space: nowrap">page&#160;II-6</FONT>
    of this registration statement.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial
    Statement Schedules
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Schedules have been omitted because the information required to
    be set forth therein is not applicable or is shown in our
    consolidated financial statements or the notes thereto.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ITEM&#160;9&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">UNDERTAKINGS</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The undersigned registrant hereby undertakes to provide to the
    underwriter at the closing specified in the underwriting
    agreements, certificates in such denominations and registered in
    such names as required by the underwriter to permit prompt
    delivery to each purchaser.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Insofar as indemnification for liabilities arising under the
    Securities Act may be permitted to directors, officers and
    controlling persons of the registrant under the provisions
    described in Item&#160;6, or otherwise, the registrant has been
    advised that in the opinion of the SEC such indemnification is
    against public policy as expressed in the Securities Act and is
    therefore unenforceable. In the event that a claim for
    indemnification against such liabilities (other than the payment
    by the registrant of expenses incurred or paid by a director,
    officer or controlling person of the registrant in the
    successful defense of any action, suit or proceeding) is
    asserted by such director, officer or controlling person in
    connection with the securities being registered, the registrant
    will, unless in the opinion of its counsel the matter has been
    settled by controlling precedent, submit to a court of
    appropriate jurisdiction the question whether such
    indemnification by it is against public policy as expressed in
    the Securities Act and will be governed by the final
    adjudication of such issue.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    II-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The undersigned registrant hereby undertakes that:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (1)&#160;For purposes of determining any liability under the
    Securities Act, the information omitted from the form of
    prospectus filed as part of this registration statement in
    reliance upon Rule&#160;430A and contained in a form of
    prospectus filed by the registrant under Rule&#160;424(b)(1) or
    (4)&#160;or 497(h) under the Securities Act shall be deemed to
    be part of this registration statement as of the time it was
    declared effective.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (2)&#160;For the purpose of determining any liability under the
    Securities Act, each post-effective amendment that contains a
    form of prospectus shall be deemed to be a new registration
    statement relating to the securities offered therein, and the
    offering of such securities at that time shall be deemed to be
    the initial bona fide offering thereof.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (3)&#160;For the purpose of determining liability under the
    Securities Act of 1933 to any purchaser, each prospectus filed
    pursuant to Rule&#160;424(b) as part of a registration statement
    relating to an offering, other than registration statements
    relying on Rule&#160;430B or other than prospectuses filed in
    reliance on Rule&#160;430A, shall be deemed to be part of and
    included in the registration statement as of the date it is
    first used after effectiveness, provided, however, that no
    statement made in a registration statement or prospectus that is
    part of the registration statement or made in a document
    incorporated or deemed incorporated by reference into the
    registration statement or prospectus that is part of the
    registration statement will, as to a purchaser with a time of
    contract of sale prior to such first use, supersede or modify
    any statement that was made in the registration statement or
    prospectus that was part of the registration statement or made
    in any such document immediately prior to such date of first use.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (4)&#160;For the purpose of determining liability of the
    registrant under the Securities Act of 1933 to any purchaser in
    the initial distribution of the securities, the undersigned
    registrant undertakes that in a primary offering of securities
    of the undersigned registrant pursuant to this registration
    statement, regardless of the underwriting method used to sell
    the securities to the purchaser, if the securities are offered
    or sold to such purchaser by means of any of the following
    communications, the undersigned registrant will be a seller to
    the purchaser and will be considered to offer or sell such
    securities to such purchaser:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (i)&#160;Any preliminary prospectus or prospectus of the
    undersigned registrant relating to the offering required to be
    filed pursuant to Rule 424;
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (ii)&#160;Any free writing prospectus relating to the offering
    prepared by or on behalf of the undersigned registrant or used
    or referred to by the undersigned registrant;
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (iii)&#160;The portion of any other free writing prospectus
    relating to the offering containing material information about
    the undersigned registrant or its securities provided by or on
    behalf of the undersigned registrant;&#160;and
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (iv)&#160;Any other communication that is an offer in the
    offering made by the undersigned registrant to the purchaser.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SIGNATURES</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the requirements of the Securities Act, the
    registrant certifies that it has reasonable grounds to believe
    that it meets all of the requirements for filing on
    <FONT style="white-space: nowrap">Form&#160;F-1</FONT>
    and has duly caused this registration statement to be signed on
    its behalf by the undersigned, thereunto duly authorized, in the
    City of Beijing, People&#146;s Republic of China, on
    December&#160;10, 2009.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 38%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="38%"></TD>
    <TD width="4%"></TD>
    <TD width="58%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Jianyu
    Yang</FONT></DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 42%; width: 48%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=222 -->

<DIV align="left" style="margin-left: 42%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Name:&#160;&#160;&#160;&#160;&#160;Jianyu Yang
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="42%"></TD>
    <TD width="7%"></TD>
    <TD width="51%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    Director, Chief Executive Officer and President
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the requirements of the Securities Act of 1933, this
    registration statement has been signed by the following persons
    in the capacities indicated on December&#160;10, 2009.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="9%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="35%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="52%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Signature</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Title</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 12pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Jianyu
    Yang</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Jianyu Yang
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Director, Chief Executive Officer and President<BR>
    (principal executive officer)
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Zheng Cheng
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Co-Chairman and Chief Operating Officer
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Steve Sun
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Co-Chairman and Chief Financial Officer<BR>
    (principal financial and accounting officer)
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Jing Zhang
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Director and Executive President
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Yaw Kong Yap
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Director and Financial Controller
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Shirley Chen
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Feng Xiao
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Elaine Zong
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Wai Hong Ku
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
<DIV style="text-indent: -23pt; margin-left: 23pt">
    * By:
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Jianyu
    Yang</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Jianyu
    Yang<BR>
    Attorney-in-fact
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SIGNATURE
    OF AUTHORIZED U.S. REPRESENTATIVE</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the Securities Act of 1933, the undersigned, the duly
    authorized representative in the United States of Concord
    Medical Services Holdings Limited, has signed this registration
    statement or amendment thereto in Newark, Delaware, on
    December&#160;10, 2009.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Authorized U.S. Representative
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    PUGLISI &#038; ASSOCIATES
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Donald
    J. Puglisi</DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Name:&#160;&#160;&#160;&#160;&#160;Donald J. Puglisi
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="8%"></TD>
    <TD width="43%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    Managing Director
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">EXHIBIT&#160;INDEX</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="8%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="90%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B>Exhibit</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Number</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Description of
    Document</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    1.1
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Underwriting Agreement
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    3.1*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Second Amended and Restated Memorandum and Articles of
    Association of the Registrant, as currently in effect
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    3.2*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Secretary&#146;s Certificate of the Registrant dated as of
    November&#160;17, 2009 as to the Amendment to the Second Amended
    and Restated Memorandum and Articles of Association of the
    Registrant
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    3.3*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Third Amended and Restated Memorandum and Articles of
    Association of the Registrant
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.1*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Registrant&#146;s American Depository Receipt (included
    in Exhibit&#160;4.3)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.2*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Specimen Certificate for Ordinary Shares of the Registrant
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.3*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Deposit Agreement among the Registrant, the Depositary
    and Owners and Beneficial Owners of the American Depository
    Shares issued thereunder
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.4*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Series&#160;A Preferred Shares Subscription Agreement, dated as
    of February&#160;5, 2008, as amended on April&#160;2, 2008 and
    on October&#160;20, 2008, among CICC Sun Company Limited,
    Carlyle Asia Growth Partners III, L.P., CAGP III Co-Investment,
    L.P., Liu Haifeng, Steve Sun, Yang Jianyu, Bona Liu, Our Medical
    Services, Ltd., Ascendium Group Limited, Shenzhen Aohua Medical
    Services Co., Ltd. and Concord Medical Services Holdings Limited
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.5*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment No.&#160;1 to Series&#160;A Preferred Shares
    Subscription Agreement, dated as of April&#160;2, 2008, among
    CICC Sun Company Limited, Carlyle Asia Growth Partners III,
    L.P., CAGP III Co-Investment, L.P., Liu Haifeng, Steve Sun, Yang
    Jianyu, Bona Liu, Our Medical Services, Ltd., Ascendium Group
    Limited, Shenzhen Aohua Medical Services Co., Ltd. and Concord
    Medical Services Holdings Limited
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.6*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment No.&#160;2 to Series&#160;A Preferred Shares
    Subscription Agreement, dated as of October&#160;20, 2008, among
    CICC Sun Company Limited, Carlyle Asia Growth Partners III,
    L.P., CAGP III Co-Investment, L.P., Liu Haifeng, Steve Sun, Yang
    Jianyu, Bona Liu, Our Medical Services, Ltd., Ascendium Group
    Limited, Shenzhen Aohua Medical Services Co., Ltd. and Concord
    Medical Services Holdings Limited
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.7*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Series&#160;B Preferred Shares Subscription Agreement, dated as
    of October&#160;10, 2008, as amended on October&#160;20, 2008,
    among CICC Sun Company Limited, Carlyle Asia Growth Partners
    III, L.P., CAGP III Co-Investment, L.P., Starr Investments
    Cayman II, Inc., Concord Medical Services Holdings Limited and
    other persons named therein
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.8*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment to Series&#160;B Preferred Shares Subscription
    Agreement, dated as of October&#160;20, 2008, among CICC Sun
    Company Limited, Carlyle Asia Growth Partners III, L.P., CAGP
    III Co-Investment, L.P., Starr Investments Cayman II, Inc.,
    Concord Medical Services Holdings Limited and other persons
    named therein
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.9*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amended and Restated Shareholders Agreement, dated as of
    October&#160;20, 2008, among Concord Medical Services Holdings
    Limited, Carlyle Asia Growth Partners III, L.P., CAGP III
    Co-Investment, CICC Sun Company Limited, Perfect Key Holdings
    Limited, Starr Investments Cayman II, Inc. and certain other
    persons named therein
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.10*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Share Charge, dated as of November 10, 2008, by CZY Investments
    Limited in favor of CICC Sun Company Limited, Carlyle Asia
    Growth Partners III, L.P., CAGP III Co-Investment, L.P. and
    Starr Investments Cayman II, Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.11*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Share Charge, dated as of November 10, 2008, by Daketala
    International Investment Holdings Ltd. in favor of CICC Sun
    Company Limited, Carlyle Asia Growth Partners III, L.P., CAGP
    III Co-Investment, L.P. and Starr Investments Cayman II, Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.12*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Share Charge, dated as of November 10, 2008, by Dragon Image
    Investment Ltd. in favor of CICC Sun Company Limited, Carlyle
    Asia Growth Partners III, L.P., CAGP III Co-Investment, L.P. and
    Starr Investments Cayman II, Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.13*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Share Charge, dated as of November 10, 2008, by Notable
    Enterprise Limited in favor of CICC Sun Company Limited, Carlyle
    Asia Growth Partners III, L.P., CAGP III Co-Investment, L.P. and
    Starr Investments Cayman II, Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.14*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Share Charge, dated as of November 10, 2008, by Thousand Ocean
    Group Limited in favor of CICC Sun Company Limited, Carlyle Asia
    Growth Partners III, L.P., CAGP III Co-Investment, L.P. and
    Starr Investments Cayman II, Inc.
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="8%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="90%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B>Exhibit</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Number</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Description of
    Document</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.15*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Share Charge, dated as of November 10, 2008, by Top Mount Group
    Limited in favor of CICC Sun Company Limited, Carlyle Asia
    Growth Partners III, L.P., CAGP III Co-Investment, L.P. and
    Starr Investments Cayman II, Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.16*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Deed of Amendment, dated as of September&#160;14, 2009, among
    CICC Sun Company Limited, Carlyle Asia Growth Partners III,
    L.P., CAGP III Co-Investment, L.P., Starr Investments Cayman II,
    Inc. and Notable Enterprise Limited
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.17*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Deed of Partial Release, dated as of September&#160;14, 2009, by
    CICC Sun Company Limited, Carlyle Asia Growth Partners III,
    L.P., CAGP III Co-Investment, L.P. and Starr Investments Cayman
    II, Inc. in favor of CZY Investment Limited
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.18*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment to Amended and Restated Shareholders Agreement, dated
    as of November&#160;17, 2009, among Concord Medical Services
    Holdings Limited, Carlyle Asia Growth Partners&#160;III, L.P.,
    CAGP&#160;III Co-Investment, CICC Sun Company Limited, Perfect
    Key Holdings Limited, Starr Investments Cayman II, Inc. and
    certain other persons named therein
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.19*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment No.&#160;2 to Amended and Restated Shareholders
    Agreement, dated as of December&#160;7, 2009, among Concord
    Medical Services Holdings Limited, Carlyle Asia Growth
    Partners&#160;III, L.P., CAGP&#160;III Co-Investment, CICC Sun
    Company Limited, Perfect Key Holdings Limited, Starr Investments
    Cayman&#160;II, Inc. and certain other persons named therein
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    5.1*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Opinion of Walkers regarding the validity of the ordinary shares
    being registered
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    8.1*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Opinion of Walkers regarding certain Cayman Islands tax matters
    (included in Exhibit&#160;5.1)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    8.2*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Opinion of Simpson Thacher&#160;&#038; Bartlett LLP regarding
    certain U.S. tax matters
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.1*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    2008&#160;Share Incentive Plan adopted as of October&#160;16,
    2008
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.2*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Indemnification Agreement with the Registrant&#146;s
    directors and officers
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.3*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Medical Equipment Lease Agreement
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.4*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Equipment Management Services Agreement
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.5*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Service-only Management Agreement
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.6*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Summary of the Oral Agreement entered into between China Medstar
    Pte. Ltd. and Beijing Medstar Hi-Tech Investment Co., Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.7*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Summary of the Oral Agreement entered into between China Medstar
    Pte. Ltd. and Cheng Zheng
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.8*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Summary of the Oral Agreement entered into between China Medstar
    Pte. Ltd. and Yaw Kong Yap
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.9*&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Medical Equipment Lease Agreement, dated as of
    August 25, 2009, by and between Medstar (Shanghai) Leasing Co.,
    Ltd. and Chang&#146;an Hospital Co., Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.10*&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Service-Only Management Agreement, dated as of
    August 1, 2008, among CMS Hospital Management Co., Ltd.,
    Xi&#146;an Wanjiechangxin Medical Services Company Limited and
    Chang&#146;an Hospital Co., Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.11*&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Agreement Concerning the Establishment of the
    Aohai Radiotherapy Treatment and Diagnosis Research Center,
    dated as of September 19, 1995, by and between the Chinese
    People&#146;s Liberation Army Navy General Hospital and Beijing
    Our Medical Equipment Development Company, which transferred its
    interest in the agreement to Shenzhen Aohua Medical Services
    Co., Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.12*&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Supplemental Agreement Concerning the Development
    of the Aohai Radiotherapy Treatment and Diagnosis Research
    Center, dated as of March 18, 1999, by and between Shenzhen
    Aohua Medical Services Co., Ltd. and the Chinese People&#146;s
    Liberation Army Navy General Hospital.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.13*&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Supplemental Agreement Concerning the Development
    of the Aohai Radiotherapy Treatment and Diagnosis Research
    Center, dated as of September 27, 2003, by and between Shenzhen
    Aohua Medical Services Co., Ltd. and the Chinese People&#146;s
    Liberation Army Navy General Hospital.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.14*&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Medical Equipment Lease Agreement, dated as of
    September 29, 2006, by and between Shanghai Medstar Investment
    Management Co., Ltd., the predecessor of Medstar (Shanghai)
    Leasing Co., Ltd., and the Chinese People&#146;s Liberation Army
    Navy General Hospital.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.15*&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Supplemental Agreement Concerning the Development
    of the Aohai Radiotherapy Treatment and Diagnosis Research
    Center, dated as of July 8, 2009, by and between Shenzhen Aohua
    Medical Services Co., Ltd. and the Chinese People&#146;s
    Liberation Army Navy General Hospital.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.16*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Supplemental Agreement to the Service-only
    Management Agreement, dated as of August 1, 2008, among
    Xi&#146;an Wanjiechangxin Medical Services Company Limited,
    Chang&#146;an Hospital Co., Ltd. and CMS Hospital Management
    Co., Ltd.
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="8%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="90%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B>Exhibit</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Number</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Description of
    Document</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.17*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Agreement Regarding the Transfer of Equity in
    Aohai Radiotherapy Treatment and Diagnosis Research Center,
    dated as of May 5, 1997, among Beijing Our Medical Equipment
    Development Company, Shenzhen Aohua Medical Services Co., Ltd.
    and the Chinese People&#146;s Liberation Army Navy General
    Hospital.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.18*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Supplemental Agreement to the Supplemental
    Agreement Concerning the Development of the Aohai Radiotherapy
    Treatment and Diagnosis Research Center, dated as of September
    15, 2004, by and between Shenzhen Aohua Medical Services Co.,
    Ltd. and the Chinese People&#146;s Liberation Army Navy General
    Hospital.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.19*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Supplemental Agreement to the Cooperation
    Contract Concerning the Aohai Radiotherapy Treatment and
    Diagnosis Research Center, dated as of August 16, 2003, by and
    between Shenzhen Aohua Medical Services Co., Ltd. and the
    Chinese People&#146;s Liberation Army Navy General Hospital.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.20*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment to 2008 Share Incentive Plan adopted as of
    November&#160;17, 2009
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.21*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Strategic Cooperative Agreement, dated as of
    November&#160;17, 2009, between China Construction Bank
    Corporation, Shenzhen Branch and China Medical Services Holdings
    Limited
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    21.1*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Subsidiaries of the Registrant
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    23.1*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Independent Registered Public Accounting Firm
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    23.2*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Walkers (included in Exhibit&#160;5.1)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    23.3*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Simpson Thacher&#160;&#038; Bartlett LLP (included in
    Exhibit&#160;8.2)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    23.4*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Jingtian&#160;&#038; Gongcheng Attorneys At Law
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    23.5*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Frost &#038; Sullivan
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    24.1*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Powers of Attorney (included on the signature page in
    Part&#160;II of this registration statement)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    99.1*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Code of Business Conduct and Ethics
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    99.2*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Opinion of Jingtian &#038; Gongcheng Attorneys At Law
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    * </TD>
    <TD></TD>
    <TD valign="bottom">
    Previously filed.</TD>
</TR>




<TR>
    <TD valign="top">
    &#134; </TD>
    <TD></TD>
    <TD valign="bottom">
    Portions of this document have been omitted pursuant to a
    confidential treatment request and the omitted information has
    been filed separately with the Securities and Exchange
    Commission.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-8
</DIV><!-- END PAGE WIDTH -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>h03611a5exv1w1.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;1.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Concord Medical Services Holdings Limited</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>&#091;12,000,000&#093; American Depositary Shares<BR>
Representing<BR>
Three Ordinary Shares, Par Value U.S.$0.0001 Per Ordinary Share</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>UNDERWRITING AGREEMENT</B>

</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">December &#091;<B>&#149;</B>&#093;, 2009
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Morgan Stanley &#038; Co. International plc<br>
J.P. Morgan Securities Inc.<br>
China International Capital Corporation Hong Kong Securities Limited,<BR>

as Representatives of the several Underwriters named in Schedule&nbsp;II hereto
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">c/o Morgan Stanley &#038; Co. International plc</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 0t; margin-left:20px">
25 Cabot Square, Canary Wharf<br>
London E14 4QA<br>
United Kingdom
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 0t; margin-left:20px">and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 0t; margin-left:20px">J.P. Morgan Securities Inc.<br>
383 Madison Avenue, Floor 4<br>
New York, New York 10179
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Ladies and Gentlemen:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concord Medical Services Holdings Limited, an exempted company incorporated in the Cayman
Islands with limited liability (the &#147;<B>Company</B>&#148;), proposes to issue and sell to the several
Underwriters named in Schedule&nbsp;II hereto (the &#147;<B>Underwriters</B>&#148;) &#091;12,000,000&#093; American Depository
Shares (the &#147;<B>ADSs</B>&#148;), each ADS representing three ordinary shares of the Company, par value
U.S.$0.0001 per share (the &#147;<B>Ordinary Shares</B>&#148;) (such &#091;12,000,000&#093; ADSs being hereinafter referred to
as the &#147;<B>Firm Shares</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain shareholders of the Company (the &#147;<B>Selling Shareholders</B>&#148;) named in Schedule&nbsp;I hereto
severally propose to sell to the several Underwriters, an aggregate of &#091;1,800,000&#093; additional ADSs
(the &#147;<B>Additional Shares</B>&#148;), each Selling Shareholder selling up to the amount set forth opposite
such Selling Shareholder&#146;s name in Schedule&nbsp;I hereto, in each case, if and to the extent that you,
as Representatives, shall have determined to exercise, on behalf of the Underwriters, the right to
purchase such Additional Shares granted to the Underwriters in Section&nbsp;3 hereof. The Firm Shares
and the Additional Shares to be outstanding after giving effect to the sales contemplated hereby,
in each case
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">including the underlying Ordinary Shares, are hereinafter collectively referred to
as the &#147;<B>Shares</B>.&#148; The Company and the Selling Shareholders are hereinafter sometimes
collectively referred to as the &#147;<B>Sellers</B>.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Shares purchased by the Underwriters will be evidenced by American depository receipts
(&#147;<B>ADRs</B>&#148;) to be issued pursuant to a deposit
agreement dated as of December &#091;<B>&#149;</B>&#093;, 2009 (the &#147;<B>Deposit
Agreement</B>&#148;) to be entered into among the Company, JPMorgan Chase Bank, N.A., as depositary (the
&#147;<B>Depositary</B>&#148;), and the holders and beneficial owners from time to time of the ADRs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is understood by all the parties that the Underwriters are offering the ADSs in the United
States and internationally outside of the People&#146;s Republic of China (the &#147;<B>PRC</B>&#148;), which, for
purposes of this Agreement only, excludes Taiwan, The Hong Kong Special Administrative Region and
The Macau Special Administrative Region.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has filed with the U.S. Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) a
registration statement on Form&nbsp;F-1 (No.&nbsp;333-163155), including a prospectus, relating to the
Shares. The registration statement as amended at the time it becomes effective, including the
information (if any) deemed to be part of the registration statement at the time of effectiveness
pursuant to Rule&nbsp;430A under the Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;), is
hereinafter referred to as the &#147;<B>Registration Statement</B>&#148;; the prospectus in the form first used to
confirm sales of Shares (or in the form first made available to the Underwriters by the Company to
meet requests of purchasers pursuant to Rule&nbsp;173 under the Securities Act) is hereinafter referred
to as the &#147;<B>Prospectus.</B>&#148; If the Company has filed an abbreviated registration statement to register
additional Ordinary Shares pursuant to Rule&nbsp;462(b) under the Securities Act (the &#147;<B>Rule&nbsp;462
Registration Statement</B>&#148;), then any reference herein to the term &#147;<B>Registration Statement</B>&#148; shall be
deemed to include such Rule&nbsp;462 Registration Statement. The Company has filed with the Commission
a registration statement on Form&nbsp;F-6 (No.&nbsp;333-163559) relating to the ADSs (such registration
statement on Form F-6, including all exhibits thereto, as amended at the time such registration
becomes effective, is hereinafter referred to as the &#147;<B>ADS Registration Statement</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Agreement, &#147;<B>free writing prospectus</B>&#148; has the meaning set forth in Rule
405 under the Securities Act, &#147;<B>Time of Sale Prospectus</B>&#148; means the preliminary prospectus, pricing
information and the free writing prospectuses, if any, identified in Schedule&nbsp;III hereto, and
&#147;<B>broadly available road show</B>&#148; means a &#147;bona fide electronic road show&#148; as defined in Rule&nbsp;433(h)(5)
under the Securities Act that has been made available without restriction to any person. As used
herein, the terms &#147;Registration Statement,&#148; &#147;preliminary prospectus,&#148; &#147;Time of Sale Prospectus&#148; and
&#147;Prospectus&#148; shall include the documents, if any, incorporated by reference therein.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 2 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Morgan Stanley &#038; Co. International plc (&#147;<B>Morgan Stanley</B>&#148;) has agreed to reserve &#091;600,000&#093;
Shares to be purchased by it under this Agreement for sale to
the Company&#146;s directors, officers, employees and business associates and other parties related
to the Company (collectively, &#147;<B>Participants</B>&#148;), as set forth in the Prospectus under the heading
&#147;Underwriting&#148; (the &#147;<B>Directed Share Program</B>&#148;). The &#091;600,000&#093; Shares to be sold by Morgan Stanley
and its affiliates pursuant to the Directed Share Program are referred to hereinafter as the
&#147;<B>Directed Shares</B>&#148;. Any Directed Shares not orally confirmed for purchase by any Participant by the
end of the business day on which this Agreement is executed will be offered to the public by the
Underwriters as set forth in the Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.<I>&nbsp;Representations and Warranties of the Company. </I>The Company represents and warrants to and
agrees with each of the Underwriters that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(a)&nbsp;</I>The Registration Statement and the ADS Registration Statement have become effective; no
stop order suspending the effectiveness of the Registration Statement or the ADS Registration
Statement is in effect; and no proceedings for such purpose are pending before or, to the knowledge
of the Company, threatened by the Commission.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(b)&nbsp;</I>(i)&nbsp;Each of the Registration Statement and the ADS Registration Statement, when it became
effective, did not contain and, as amended or supplemented, if applicable, will not contain any
untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein not misleading, (ii)&nbsp;the Registration Statement, the
Prospectus and the ADS Registration Statement comply and, as amended or supplemented, if
applicable, will comply in all material respects with the Securities Act and the applicable rules
and regulations of the Commission thereunder, (iii)&nbsp;the Time of Sale Prospectus does not, and at
the time of each sale of the Shares in connection with the offering when the Prospectus is not yet
available to prospective purchasers and at the Closing Date (as defined in Section&nbsp;6), the Time of
Sale Prospectus, as then amended or supplemented by the Company, if applicable, will not, contain
any untrue statement of a material fact or omit to state a material fact necessary to make the
statements therein, in the light of the circumstances under which they were made, not misleading,
(iv)&nbsp;each broadly available road show, if any, when considered together with the Time of Sale
Prospectus, does not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements therein, in the light of the circumstances under which they
were made, not misleading, and (v)&nbsp;the Prospectus does not contain and, as amended or supplemented,
if applicable, will not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements therein, in the light of the circumstances under which they
were made, not misleading, except that the representations and warranties set forth in this
paragraph do not apply to statements or omissions in the Registration Statement, the Time of Sale
Prospectus or the Prospectus based
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 3 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">upon information relating to any Underwriter furnished to the
Company in writing by such Underwriter through you expressly for use therein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(c)&nbsp;</I>The Company is not an &#147;ineligible issuer&#148; in connection with the offering pursuant to
Rules&nbsp;164, 405 and 433 under the Securities Act. Any free writing prospectus that the Company is
required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with
the Commission in accordance with the requirements of the Securities Act and the applicable rules
and regulations of the Commission thereunder. Each free writing prospectus that the Company has
filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was
prepared by or on behalf of or used or referred to by the Company complies or will comply in all
material respects with the requirements of the Securities Act and the applicable rules and
regulations of the Commission thereunder. Except for the free writing prospectuses, if any,
identified in Schedule&nbsp;III hereto, and electronic road shows, if any, each furnished to you before
first use, the Company has not prepared, used or referred to, and will not, without your prior
consent, prepare, use or refer to, any free writing prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(d)&nbsp;</I>The Company has been duly organized, is validly existing as an exempted company in good
standing under the laws of the Cayman Islands, has the corporate power and authority to own its
property and to conduct its business as described in the Time of Sale Prospectus and is duly
qualified to transact business and is in good standing in each jurisdiction in which the conduct of
its business or its ownership or leasing of property requires such qualification, except to the
extent that the failure to be so qualified or be in good standing would not have a material adverse
effect on the Company and its subsidiaries, taken as a whole.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(e)&nbsp;</I>The Company does not own or control, directly or indirectly, any corporation, association
or entity other than as set forth in the Time of Sale Prospectus. Each subsidiary of the Company
has been duly organized, is validly existing as a corporation in good standing under the laws of
the jurisdiction of its incorporation, has the corporate power and authority to own its property
and to conduct its business as described in the Time of Sale Prospectus and is duly qualified to
transact business and is in good standing in each jurisdiction in which the conduct of its business
or its ownership or leasing of property requires such qualification, except to the extent that the
failure to be so qualified or be in good standing would not have a material adverse effect on the
Company and its subsidiaries, taken as a whole; all of the issued shares of capital stock of each
subsidiary of the Company have been duly and validly authorized and issued, are fully paid and
non-assessable and are owned directly by the Company, free and clear of all liens, encumbrances,
equities or claims.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(f)&nbsp;</I>This Agreement has been duly authorized, executed and delivered by the Company.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 4 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(g)&nbsp;</I>The authorized share capital of the Company conforms in all material respects as to legal
matters to the description thereof contained in each of the Time of Sale Prospectus and the
Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(h)&nbsp;</I>The outstanding Ordinary Shares and all other outstanding shares of the Company prior to
the issuance of the Shares have been duly authorized and are validly issued, fully paid and
non-assessable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(i)&nbsp;</I>The Shares have been duly authorized and, when issued and delivered in accordance with the
terms of this Agreement and the Deposit Agreement, as the case may be, will be validly issued,
fully paid and non-assessable, and the issuance of such Shares will not be subject to any
preemptive or similar rights.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(j)&nbsp;</I>The Shares to be sold by the Company, when issued and delivered against payment heretofore
pursuant to this Agreement, will not be subject to any security interest, other encumbrance or
adverse claims, and will have been issued in compliance with all U.S. federal, state and foreign
securities laws and will not have been issued in violation of any preemptive right, resale right,
right of first refusal or similar right; upon payment of the purchase price in accordance with this
Agreement on the Closing Date, the Depositary or its nominee, as the registered holder of the
Ordinary Shares represented by the ADSs, will be, subject to the terms of the Deposit Agreement,
entitled to all the rights of a shareholder conferred by the Memorandum and Articles of Association
of the Company, as amended from time to time (the &#147;<B>Memorandum and Articles of Association</B>&#148;); except
as disclosed in the Time of Sale Prospectus and subject to the terms and provisions of the Deposit
Agreement, there are no restrictions on transfers of Ordinary Shares represented by the ADSs or the
ADSs under the laws of the Cayman Islands, the PRC or the United States, as the case may be; the
Ordinary Shares represented by the Shares may be freely deposited by the Company with the
Depositary or its nominee against issuance of ADRs evidencing the ADSs as contemplated by the
Deposit Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(k)&nbsp;</I>The execution and delivery by the Company of, and the performance by the Company of its
obligations under, this Agreement and the Deposit Agreement will not contravene any provision of
applicable law or the Memorandum and Articles of Association or any other organizational documents
of the Company or any agreement or other instrument binding upon the Company or any of its
subsidiaries that is material to the Company and its subsidiaries, taken as a whole, or any
judgment, order or decree of any governmental body, agency or court having jurisdiction over the
Company or any subsidiary, and no consent, approval, authorization or order of, or qualification
with (&#147;<B>Governmental Authorization</B>&#148;), any governmental body or agency (&#147;<B>Governmental Agency</B>&#148;) is
required for the performance by the Company of its obligations under this Agreement of the Deposit
Agreement in connection with
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 5 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the offer, issuance and sale of the Shares by the Company and the
deposit of the Ordinary Shares with the Depositary against issuance of ADRs evidencing the ADSs,
except such as may be required by the securities or Blue Sky laws of the various states in
connection with the offer and sale of the Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(l)&nbsp;</I>Neither the Company nor any of its subsidiaries is in violation of its respective
organizational documents or in default (or with the giving of notice or lapse of time would be in
default) under any existing obligation, agreement, covenant or condition contained in any
indenture, loan agreement, mortgage, lease or other agreement or instrument to which any of them is
a party or by which any of them is bound or to which any of the properties of any of them is
subject, other than violations or defaults that would not have a material adverse effect on the
Company and its subsidiaries, taken as a whole.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(m)&nbsp;</I>Except as disclosed in the Time of Sale Prospectus under the headings &#147;Risk
Factors&#150;Certain of our hospital partners have not received large medical equipment procurement
licenses or interim procurement permits for some of the medical equipment in our network or centers
which could result in fines or the suspension from use of such medical equipment&#148; and
&#147;Regulation&#150;Regulation of Medical Institutions&#150;Large Medical Procurement License,&#148; neither the
Company nor any of its subsidiaries is (i)&nbsp;in breach of or in default under any laws, regulations,
rules, orders, decrees, guidelines or notices of the PRC, the Cayman Islands or any other
jurisdiction where it is incorporated or operates, or (ii)&nbsp;in breach of or in default under any
Governmental Authorization of any Governmental Agency in the PRC, the Cayman Islands or any other
jurisdiction where it was incorporated or operates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(n)&nbsp;</I>There has not occurred any material adverse change, or any development involving a
prospective material adverse change, in the condition, financial or otherwise, or in the earnings,
business or operations of the Company and its subsidiaries, taken as a whole, from that set forth
in the Time of Sale Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(o)&nbsp;</I>There are no legal or governmental proceedings pending or, to the knowledge of the
Company, threatened to which the Company, any of its subsidiaries or any of its or their officers
and directors is a party or to which any of the properties of the Company or any of its
subsidiaries is subject (i)&nbsp;other than proceedings accurately described in all material respects in
the Time of Sale Prospectus and proceedings that would not have a material adverse effect on the
Company and its subsidiaries, taken as a whole, or on the power or ability of the Company to
perform its obligations under this Agreement or to consummate the transactions contemplated by the
Time of Sale Prospectus, or (ii)&nbsp;that are required to be described in the Registration Statement or
the Prospectus and are not so described; and there are no statutes, regulations, contracts or other
documents that are required to be described in the Registration Statement or the Prospectus or to
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 6 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">be filed as exhibits to the Registration Statement that are not described or filed as required.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(p)&nbsp;</I>Each preliminary prospectus filed as part of the registration statement as originally
filed or as part of any amendment thereto, or filed pursuant to Rule&nbsp;424 under the Securities Act,
complied when so filed in all material
respects with the Securities Act and the applicable rules and regulations of the Commission
thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(q)&nbsp;</I>The Company is not, and after giving effect to the offering and sale of the Shares and the
application of the proceeds thereof as described in the Prospectus will not be, required to
register as an &#147;investment company&#148; as such term is defined in the Investment Company Act of 1940,
as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(r)&nbsp;</I>Except as disclosed in the Time of Sale Prospectus: (a)(i)&nbsp;neither the Company nor any of
its subsidiaries is in violation of, or has any liability under, any local, domestic or foreign
statute, law, rule, regulation, ordinance, code, other requirement or rule of law (including common
law), or decision or order of any domestic or foreign governmental agency, governmental body or
court, relating to pollution, to the use, handling, transportation, treatment, storage, discharge,
disposal or release of Hazardous Substances (as defined below), to the protection or restoration of
the environment or natural resources (including biota), to health and safety including as such
relates to exposure to Hazardous Substances, and to natural resource damages (collectively,
&#147;<B>Environmental Laws</B>&#148;), (ii)&nbsp;neither the Company nor any of its subsidiaries is conducting or
funding any investigation, remediation, remedial action or monitoring of actual or suspected
Hazardous Substances in the environment, (iii)&nbsp;neither the Company nor any of its subsidiaries is
liable or allegedly liable for any release or, to the knowledge of the Company, threatened release
of Hazardous Substances, including at any off-site treatment, storage or disposal site,
(iv)&nbsp;neither the Company nor any of its subsidiaries is subject to any claim by any Governmental
Agency or person relating to Environmental Laws or Hazardous Substances, and (v)&nbsp;the Company and
its subsidiaries have received and are in compliance with all, and have no liability under any,
permits, licenses, authorizations, identification numbers or other approvals required under
applicable Environmental Laws to conduct their respective businesses; (b)&nbsp;the Company is not aware
of any facts or circumstances that would reasonably be expected to result in a violation of,
liability under, or claim pursuant to any Environmental Law that would have a material adverse
effect on the Company and its subsidiaries, taken as a whole; (c)&nbsp;to the Company&#146;s knowledge, there
are no requirements proposed for adoption or implementation under any Environmental Law that would
reasonably be expected to have a material adverse effect on the Company and its subsidiaries, taken
as a whole; and (d)&nbsp;in the ordinary course of its business, the Company periodically evaluates the
effect, including associated costs and liabilities, of Environmental Laws on the business,
properties, results of operations and financial condition of it
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 7 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and its subsidiaries, and, on the
basis of such evaluation, the Company has reasonably concluded that such Environmental Laws will
not have a material adverse effect on the Company and its subsidiaries, taken as a whole. For
purposes of this Agreement, &#147;<B>Hazardous Substances</B>&#148; means (A)&nbsp;radioactive materials and medical
waste and (B)&nbsp;any other chemical, material or substance defined or regulated as toxic or hazardous
or as a pollutant, biohazard, contaminant or waste under Environmental Laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(s)&nbsp;</I>There are no contracts, agreements or understandings between the Company and any person
granting such person the right to require the Company to file a registration statement under the
Securities Act with respect to any securities of the Company or to require the Company to include
such securities with the Shares registered pursuant to the Registration Statement other than
contracts, agreements or understandings accurately described in all material respects in the Time
of Sale Prospectus, and any person to whom the Company has granted such rights has agreed not to
exercise such rights until after the expiration of the 180-day restricted period referred to in
Section&nbsp;3.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(t)&nbsp;</I>Neither the Company nor any of its subsidiaries or affiliates, nor any director, officer,
or employee, nor, to the knowledge of the Company, any agent or representative of the Company or of
any of its subsidiaries or affiliates, has taken or will take any action in furtherance of an
offer, payment, promise to pay, or authorization or approval of the payment or giving of money,
property, gifts or anything else of value, directly or indirectly, to any &#147;government official&#148;
(including any officer or employee of a government or government-owned or controlled entity or of a
public international organization, or any person acting in an official capacity for or on behalf of
any of the foregoing, or any political party or party official or candidate for political office)
to influence official action or secure an improper advantage; and the Company and its subsidiaries
and affiliates have conducted their businesses in compliance with all applicable anti-corruption
laws and have instituted and maintain and will continue to maintain policies and procedures
designed to promote and achieve compliance with such laws and with the representation and warranty
contained herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(u)&nbsp;</I>The operations of the Company and its subsidiaries are and have been conducted at all
times in material compliance with all applicable financial recordkeeping and reporting
requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting and
Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism
Act of 2001 (USA PATRIOT Act), and the applicable anti-money laundering statutes of jurisdictions
where the Company and its subsidiaries conduct business, the rules and regulations thereunder and
any related or similar rules, regulations or guidelines, issued, administered or enforced by any
governmental agency (collectively, the &#147;<B>Anti-Money Laundering Laws</B>&#148;), and no action, suit or
proceeding by or before any court or governmental agency, authority or body or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 8 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">any arbitrator
involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is
pending or, to the knowledge of the Company, threatened.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(v)&nbsp;</I>(i)&nbsp;The Company represents that neither the Company nor any of its subsidiaries
(collectively, the &#147;<B>Entity</B>&#148;) or, to the knowledge of the Company after due inquiry, any director,
officer, employee, agent, affiliate or representative of the Entity, is an individual or entity
(&#147;<B>Person</B>&#148;) that is, or is owned or controlled by a Person that is:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) the subject of any sanctions administered or enforced by the U.S.
Department of Treasury&#146;s Office of Foreign Assets Control (&#147;<B>OFAC</B>&#148;) or other
relevant sanctions authority (collectively, &#147;<B>Sanctions</B>&#148;), nor
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) located, organized or resident in a country or territory that is the
subject of Sanctions (including, without limitation, Burma/Myanmar, Cuba, Iran,
North Korea, Sudan and Syria).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;The Entity represents and covenants that it will not, directly or indirectly, use the
proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any
subsidiary, joint venture partner or other Person:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) to fund or facilitate any activities or business of or with any Person
or in any country or territory that, at the time of such funding or facilitation,
is the subject of Sanctions; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) in any other manner that will result in a violation of Sanctions by any
Person (including any Person participating in the offering, whether as
underwriter, advisor, investor or otherwise).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;The Entity represents and covenants that it has not knowingly engaged in, is not now
knowingly engaged in, and will not engage in, any dealings or transactions with any Person, or in
any country or territory, that at the time of the dealing or transaction is or was the subject of
Sanctions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(w)&nbsp;Subsequent to the respective dates as of which information is given in each of the
Registration Statement, the Time of Sale Prospectus and the Prospectus, (i)&nbsp;the Company and its
subsidiaries have not incurred any material liability or obligation, direct or contingent, nor
entered into any material transaction; (ii)&nbsp;the Company has not purchased any of its outstanding
shares, nor declared, paid or otherwise made any dividend or distribution of any kind on its shares
other than ordinary and customary dividends, and (iii)there has not been any material change in the
share capital, short-term debt or long-term debt of the Company and its subsidiaries, except in
each case as described in each of the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 9 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Registration Statement, the Time of Sale Prospectus and the
Prospectus, respectively.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(x)&nbsp;</I>The Company and its subsidiaries have good and marketable title in fee simple to all real
property and good and marketable title to all personal property owned by them which is material to
the business of the Company and its subsidiaries, in each case free and clear of all liens,
encumbrances and defects except such as are described in the Time of Sale Prospectus or such as do
not materially affect the value of such property and do not interfere with the use made and
proposed to be made of such property by the Company and its subsidiaries; and any real property and
buildings held under lease by the Company and its subsidiaries are held by them under valid,
subsisting and enforceable leases with
such exceptions as are not material and do not interfere with the use made and proposed to be
made of such property and buildings by the Company and its subsidiaries, in each case except as
described in the Time of Sale Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(y)&nbsp;</I>The Company and its subsidiaries own or possess, or can acquire on reasonable terms, all
material patents, patent rights, licenses, inventions, copyrights, trademarks service marks, trade
names, domain names, know-how (including trade secrets and other unpatented and/or unpatentable
proprietary or confidential information, systems or procedures) and other intellectual property and
similar rights, including registrations and applications for registration thereof, currently
employed by them in connection with the business now operated by them, and neither the Company nor
any of its subsidiaries has received any notice of infringement of or conflict with asserted rights
of others with respect to any of the foregoing which, singly or in the aggregate, if the subject of
an unfavorable decision, ruling or finding, would have a material adverse effect on the Company and
its subsidiaries, taken as a whole.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(z)&nbsp;</I>No material labor dispute with the employees of the Company or any of its subsidiaries
exists, except as described in the Time of Sale Prospectus, or, to the knowledge of the Company, is
imminent; and the Company is not aware of any existing, threatened or imminent labor disturbance by
the employees of any of its principal suppliers, manufacturers or contractors that could have a
material adverse effect on the Company and its subsidiaries, taken as a whole.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(aa)&nbsp;</I>The Company and each of its subsidiaries are insured by insurers of recognized financial
responsibility against such losses and risks and in such amounts as are prudent and customary in
the businesses in which they are engaged; neither the Company nor any of its subsidiaries has been
refused any insurance coverage applied for; and neither the Company nor any of its subsidiaries has
any reason to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers as may be necessary to
continue its business at a cost that would not have a material adverse effect on the Company and
its
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 10 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">subsidiaries, taken as a whole, except as described in the Time of Sale Prospectus. The
Company has obtained directors&#146; and officers&#146; insurance in such amounts and scope of coverage as is
customary in connection with an initial public offering of a PRC-based company in the United States
and listing on a U.S. stock exchange, including, without limitation, coverage for liabilities or
losses arising under the Securities Act, the Exchange Act and the applicable rules and regulations
of the Commission thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(bb)&nbsp;</I>The Company and its subsidiaries possess all certificates, licenses, franchises,
authorizations and permits necessary to conduct their respective businesses, and neither the
Company nor any of its subsidiaries has received any notice of proceedings relating to the
revocation or modification of any such certificate, license, franchise, authorization or permit
which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding,
would have
a material adverse effect on the Company and its subsidiaries, taken as a whole, except as
described in the Time of Sale Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(cc)&nbsp;</I>Except as described in the Time of Sale Prospectus, the Company, its subsidiaries and the
Company&#146;s Board of Directors (the &#147;<B>Board</B>&#148;) are in compliance with the Sarbanes-Oxley Act of 2002
(the &#147;<B>Sarbanes-Oxley Act</B>&#148;) to the extent applicable and all applicable rules (the &#147;<B>Exchange Rules</B>&#148;)
of the New York Stock Exchange (the &#147;<B>NYSE</B>&#148;); the Company and its subsidiaries maintain a system of
internal controls, including, but not limited to, disclosure controls and procedures, internal
controls over accounting matters and financial reporting, an internal audit function and legal and
regulatory compliance controls (collectively, &#147;<B>Internal Controls</B>&#148;) sufficient to provide reasonable
assurance that (i)transactions are executed in accordance with management&#146;s general or specific
authorizations, (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial
statements in conformity with U.S. generally accepted accounting principles (&#147;<B>U.S. GAAP</B>&#148;) and to
maintain asset accountability, (iii)&nbsp;access to assets is permitted only in accordance with
management&#146;s general or specific authorization, and (iv)&nbsp;the recorded accountability for assets is
compared with the existing assets at reasonable intervals and appropriate action is taken with
respect to any differences and (v)&nbsp;the Company has made and kept books, records and accounts which,
in reasonable detail, accurately and fairly reflect in all material respects the transactions and
dispositions of the Company and its subsidiaries. The Internal Controls, upon consummation of the
offering of the Shares will be, overseen by the Audit Committee (the &#147;<B>Audit Committee</B>&#148;) of the
Board in accordance with Exchange Rules. Except as disclosed in the Time of Sale Prospectus, the
Company has not publicly disclosed or reported to the Audit Committee or the Board, and the Company
does not reasonably expect to publicly disclose or report to the Audit Committee or the Board, a
significant deficiency, material weakness, change in Internal Controls or fraud involving
management or other employees who have a significant role in Internal Controls (each, an &#147;<B>Internal
Control Event</B>&#148;), any violation of, or failure to comply with, the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 11 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Securities Laws, or any matter
which, if determined adversely, would have a material adverse effect on the Company and its
subsidiaries, taken as a whole. Each of the Company&#146;s independent directors meets the U.S.
criteria for &#147;independence&#148; under the Sarbanes-Oxley Act and the Exchange Rules.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(dd)&nbsp;Except as described in the Time of Sale Prospectus, the Company has not sold, issued or
distributed any Ordinary Shares during the six-month period preceding the date hereof, including
any sales pursuant to Rule&nbsp;144A under, or Regulation&nbsp;D or S of, the Securities Act, other than
shares issued pursuant to employee benefit plans, qualified stock option plans or other employee
compensation plans or pursuant to outstanding options, rights or warrants.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ee)&nbsp;The Registration Statement, the Prospectus, the Time of Sale Prospectus and any
preliminary prospectus comply, and any amendments or supplements thereto will comply, with any
applicable laws or regulations of
foreign jurisdictions in which the Prospectus, the Time of Sale Prospectus or any preliminary
prospectus, as amended or supplemented, if applicable, are distributed in connection with the
Directed Share Program.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(ff)&nbsp;</I>No consent, approval, authorization or order of, or qualification with, any governmental
body or agency, other than those obtained, is required in connection with the offering of the
Directed Shares in any jurisdiction where the Directed Shares are being offered.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(gg)&nbsp;</I>The Company has not offered, or caused Morgan Stanley to offer, Shares to any person
pursuant to the Directed Share Program with the specific intent to unlawfully influence (i)&nbsp;a
customer or supplier of the Company to alter the customer&#146;s or supplier&#146;s level or type of business
with the Company, or (ii)&nbsp;a trade journalist or publication to write or publish favorable
information about the Company or its products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(hh)&nbsp;</I>Except as disclosed in the Time of Sale Prospectus, there are no contracts, agreements or
understandings between the Company or any of its subsidiaries and any person that would give rise
to a valid claim against the Company or any of its subsidiaries or any Underwriter for a brokerage
commission, finder&#146;s fee or other like payment in connection with this offering.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(ii)&nbsp;</I>The Shares have been approved for listing on the NYSE, subject to notice of issuance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(jj)&nbsp;</I>The execution, delivery and performance of this Agreement and the Deposit Agreement and
the consummation of the transactions contemplated herein and therein, and the issuance and sale of
the Shares, including the deposit of the Ordinary Shares with the Depositary and the issuance of
the ADRs evidencing the ADSs and the listing of the Shares on the NYSE, do not and will
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 12 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">not result
in a breach or violation of any of the terms and provisions of, or constitute a default under, or
result in the imposition of any lien, charge or encumbrance upon any property or assets of the
Company or any of its subsidiaries pursuant to, the organizational documents of the Company or any
of its subsidiaries, any statute, rule, regulation or order of any governmental agency or body or
any court, domestic or foreign, having jurisdiction over the Company or any of its subsidiaries or
any of their properties, or any agreement or instrument to which the Company or any of its
subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any
of the properties of the Company or any of its subsidiaries is subject.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(kk)&nbsp;</I>No Governmental Authorization is required for the validity, enforceability or
effectiveness of any agreement, indenture, loan agreement, mortgage, lease or other agreement or
instrument to which the Company or any of its subsidiaries is a party or by which any of them is
bound or to which any of the properties of any of them is subject (the &#147;<B>Company Contracts</B>&#148;), except
where such lack of Governmental Authorization would not have a material adverse
effect on the Company and its subsidiaries, taken as a whole; neither the Company nor any of
its subsidiaries has sent or received any communication regarding termination of, or intent not to
renew, any of the Company Contracts and no such termination or non-renewal has been threatened by
the Company or any of its subsidiaries or, to the knowledge of the Company, any other party to any
such contract or agreement other than termination or intent not to renew of such contract or
agreement that would not reasonably be expected to have a material adverse effect on the Company
and its subsidiaries, taken as a whole; and neither the Company or its subsidiaries nor, to the
knowledge of the Company, any other party to any Company Contracts is in violation or breach of any
PRC, Cayman Islands, national, provincial, municipal or other local law, regulation, statute, rule
or order, which violation or breach could invalidate, impair or result in any fine, penalty or
government sanction with regard to any Company Contracts, except as disclosed in the Time of Sale
Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(ll)&nbsp;</I>The Deposit Agreement has been duly authorized, executed and delivered by the Company
and, assuming due authorization, execution and delivery by the Depositary, constitutes a legal,
valid and binding agreement of the Company enforceable against the Company in accordance with its
terms, except as enforcement thereof may be limited by bankruptcy, insolvency, fraudulent transfer,
reorganization, moratorium and similar laws of general applicability relating to or affecting
creditors&#146; rights and to general principles of equity; upon due issuance by the Depositary of ADRs
evidencing ADSs against the deposit of the Ordinary Shares in respect thereof in accordance with
the Deposit Agreement, such ADRs will be duly and validly issued and the holders and beneficial
owners thereof will be entitled to the rights specified therein and in the Deposit Agreement; and
the Deposit Agreement and the ADRs conform in all material
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 13 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">respects to the descriptions thereof
contained in the Prospectus and the Time of Sale Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(mm)&nbsp;</I>The statements in the Time of Sale Prospectus under the headings Prospectus Summary&#150;Our
History and Corporate Structure,&#148; &#147;Risk Factors,&#148; &#147;Dividend Policy,&#148; &#147;Enforcement of Civil
Liabilities,&#148; &#147;Our History and Corporate Structure,&#148; &#147;Business,&#148; &#147;Regulation of Our Industry,&#148;
&#147;Management,&#148; &#147;Related Party Transactions,&#148; &#147;Description of Share Capital,&#148; &#147;Description of
American Depositary Shares,&#148; &#147;Share Eligible for Future Sale,&#148; &#147;Taxation&#148; and &#147;Underwriting&#148;
insofar as such statements summarize legal matters, agreements, documents or proceedings discussed
therein, are accurate and fair summaries in all material respects of such legal matters,
agreements, documents or proceedings and include the information required to be included therein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(nn)&nbsp;</I>The Company has not taken, directly or indirectly, any action that is designed to or that
has constituted or that would reasonably be expected to cause or result in the stabilization or
manipulation of the price of any security of the Company to facilitate the sale or resale of the
Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(oo)&nbsp;</I>Any third-party statistical and market-related data included in the Registration
Statement, the Prospectus or the Time of Sale Prospectus are based on or derived from sources that
the Company believes to be reliable and accurate, and relevant third-party consents for such data
to be included therein have been duly obtained and have not been revoked.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(pp)&nbsp;</I>Except as disclosed in the Time of Sale Prospectus, neither the Company&#146;s independent
auditors nor its internal auditors have recommended that the Board review or investigate, (i)
adding to, deleting, changing the application of, or changing the Company&#146;s disclosure with respect
to, any of the Company&#146;s material accounting policies, (ii)&nbsp;any matter which could result in a
restatement of the Company&#146;s financial statements for any annual or interim period during the
current or prior three fiscal years, or (iii)&nbsp;any Internal Control Event.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(qq)&nbsp;</I>The section entitled &#147;Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations&#148; in the Time of Sale Prospectus accurately and fully describes (i)&nbsp;accounting
policies that the Company believes are the most important in the portrayal of the financial
condition and results of operations of the Company and its subsidiaries and that require
management&#146;s most difficult, subjective or complex judgments (&#147;<B>Critical Accounting Policies</B>&#148;),
(ii)&nbsp;judgments and uncertainties affecting the application of Critical Accounting Policies, and
(iii)&nbsp;the likelihood that materially different amounts would be reported under different conditions
or using different assumptions and an explanation thereof; and the Board and the Company&#146;s
management have reviewed and agreed with the selection, application and disclosure of the Critical
Accounting Policies as described in the Time of Sale Prospectus.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 14 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(rr)&nbsp;</I>The financial statements included in the Registration Statement, the Prospectus and the
Time of Sale Prospectus comply as to form in all material respects with the requirements of the
Securities Act and the rules and regulations of the Commission thereunder and present fairly the
financial position of the Company and its consolidated subsidiaries as of the dates shown and their
results of operations, shareholders equity and cash flows for the periods shown, and such financial
statements have been prepared in conformity with U.S. GAAP applied on a consistent basis; the
schedules included in the Registration Statement present fairly the information required to be
stated therein; and the selected financial data and the summary financial information included in
the Registration Statement, the Prospectus and the Time of Sale Prospectus present fairly the
information shown therein and have been compiled on a basis consistent with that of the audited
financial statements included in the Registration Statement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(ss)&nbsp;</I>Ernst &#038; Young Hua Ming, who has expressed an opinion on the financial statements of the
Company included in the Registration Statement, the Prospectus and the Time of Sale Prospectus
based on its audits, is an independent public accounting firm as required by the Securities Act and
the rules and regulations of the Commission thereunder and is registered with, and is
independent in accordance with the requirements of, the Public Company Accounting Oversight
Board.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(tt)&nbsp;</I>The Company was not a &#147;passive foreign investment company&#148; (&#147;<B>PFIC</B>&#148;) as defined in Section
1297 of the U.S. Internal Revenue Code of 1986, as amended, for its most recently completed taxable
year and, based on the Company&#146;s current projected income, assets and activities, the Company does
not expect to be classified as a PFIC for 2009 or any subsequent taxable year.<SUP style="font-size: 85%; vertical-align: text-top"> </SUP>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(uu)&nbsp;</I>Except as disclosed in the Time of Sale Prospectus, under current laws and regulations of
the Cayman Islands, Hong Kong, the PRC and any political subdivision thereof, all dividends and
other distributions declared and payable on the Shares may be paid by the Company to the holder
thereof in U.S. dollars that may be converted into foreign currency and freely transferred out of
the Cayman Islands, Hong Kong or the PRC and all such payments made to holders thereof or therein
who are non-residents of the Cayman Islands, Hong Kong or the PRC will not be subject to income,
withholding or other taxes under laws and regulations of the Cayman Islands, Hong Kong, the PRC or
any political subdivision or taxing authority thereof or therein and will otherwise be free and
clear of any other tax, duty, withholding or deduction in the Cayman Islands, Hong Kong, the PRC or
any political subdivision or taxing authority thereof or therein and without the necessity of
obtaining any Governmental Authorization in the Cayman Islands, Hong Kong, the PRC or any political
subdivision or taxing authority thereof or therein.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->- 15 -<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(vv)&nbsp;</I>There are no material relationships or transactions within the past three years between
the Company or any of its subsidiaries on the one hand and their respective affiliates, directors
or officers or 10% or greater shareholders, or any affiliates or members of the immediate families
of such persons, on the other hand that are not disclosed in the Time of Sale Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(ww)&nbsp;</I>Except as set forth in the Time of Sale Prospectus, there are no affiliations or
associations between any member of the Financial Industry Regulatory Authority, Inc. (&#147;<B>FINRA</B>&#148;) and
the Company or any of its subsidiaries or between any member of FINRA, any of the officers or
directors of the Company, or holders of 5% or greater of the securities of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(xx)&nbsp;</I>The Company is a &#147;foreign private issuer&#148; within the meaning of Rule&nbsp;405 under the
Securities Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(yy)&nbsp;</I>The Company and its subsidiaries have filed all Cayman Islands, Hong Kong, PRC and other
tax returns, if any, that are required to be filed or have requested extensions thereof (except in
any case in which the failure to file would not, individually or in the aggregate, have a material
adverse effect on the Company and its subsidiaries, taken as a whole; except as set forth in the
Time of Sale Prospectus, the Company and its subsidiaries have paid all taxes (including any
assessments, fines or penalties) required to be paid by them, except for any
such taxes, assessments, fines or penalties currently being contested in good faith as would
not, individually or in the aggregate, have a material adverse effect on the Company and its
subsidiaries, taken as a whole; neither the Company nor any of its subsidiaries has received a
notice of deficiency with respect to the Company or any of its subsidiaries, except for such
notices the effect of which would not have a material adverse effect on the Company and its
subsidiaries, taken as a whole; and the provisions included in the audited consolidated financial
statements contained in the Prospectus and the Time of Sale Prospectus are in conformity with U.S.
GAAP.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(zz)&nbsp;</I>Except as disclosed in the Time of Sale Prospectus, no transaction, stamp, capital or
other issuance, registration, transaction, transfer or withholding taxes or duties are payable in
the PRC, Hong Kong and the Cayman Islands by or on behalf of the Underwriters to any PRC, Hong Kong
or Cayman Islands taxing authority in connection with (i)&nbsp;the issuance, sale and delivery of the
Ordinary Shares represented by the Shares by the Company and the Selling Shareholders, the issuance
of the Shares by the Depositary, and the delivery of the Shares to or for the account of the
Underwriters, (ii)&nbsp;the purchase from the Company and the initial sale and delivery by the
Underwriters of the Shares to purchasers thereof, (iii)&nbsp;the deposit of the Ordinary Shares with the
Depositary and the Custodian (as defined in the Deposit Agreement) and the issuance and delivery of
the ADRs evidencing the ADSs, or (iv)&nbsp;the execution and delivery of this Agreement or the Deposit
Agreement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 16 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(aaa) </I>This Agreement and the Deposit Agreement are in proper form under the laws of the Cayman
Islands for the enforcement thereof against the Company in accordance with the laws of the Cayman
Islands and to ensure the legality, validity, enforceability or admissibility into evidence in the
Cayman Islands of this Agreement and the Deposit Agreement; it is not necessary that this
Agreement, the Deposit Agreement or any other document be filed or recorded with any Governmental
Authority in the Cayman Islands or that any Cayman Islands stamp duty or similar tax be paid on or
in respect of this Agreement, the Deposit Agreement or any other document to be furnished hereunder
or thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(bbb) </I>The choice of laws of the State of New York as the governing law of this Agreement and
the Deposit Agreement is a valid choice of law under the laws of the Cayman Islands and the PRC and
will be honored by courts in the Cayman Islands and, to the extent permitted under the PRC civil
law and rules of civil procedures, will be honored by the courts in the PRC. The Company has the
power to submit, and pursuant to Section&nbsp;17 of this Agreement and Section&nbsp;19 of the Deposit
Agreement, has legally, validly, effectively and irrevocably submitted, to the personal
jurisdiction of each U.S. federal court and New York state court located in the Borough of
Manhattan, in The City of New York, New York, U.S.A. (each, a &#147;<B>New York Court</B>&#148;), and the Company
has the power to designate, appoint and authorize, and pursuant to Section&nbsp;17 of this Agreement and
Section&nbsp;19 of the Deposit Agreement, has legally, validly, effectively and
irrevocably designated, appointed and authorized an agent for service of process in any action
arising out of or relating to this Agreement, the Deposit Agreement or the Shares in any New York
Court, and service of process effected on such authorized agent will be effective to confer valid
personal jurisdiction over the Company as provided in Section&nbsp;17 hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(ccc)&nbsp;</I>Neither the Company, nor any of its subsidiaries nor any of their respective properties,
assets or revenues has any right of immunity under Cayman Islands, PRC, Hong Kong or New York law,
from any legal action, suit or proceeding, from the giving of any relief in any such legal action,
suit or proceeding, from set-off or counterclaim, from the jurisdiction of any Cayman Islands, PRC,
Hong Kong, New York or U.S. federal court, from service of process, attachment upon or prior to
judgment, or attachment in aid of execution of judgment, or from execution of a judgment, or other
legal process or proceeding for the giving of any relief or for the enforcement of a judgment, in
any such court, with respect to its obligations, liabilities or any other matter under or arising
out of or in connection with this Agreement or the Deposit Agreement, and, to the extent that the
Company, or any of its subsidiaries or any of their respective properties, assets or revenues may
have or may hereafter become entitled to any such right of immunity in any such court in which
proceedings may at any time be commenced, each of the Company and its subsidiaries waives
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 17 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">or will
waive such right to the extent permitted by law and has consented to such relief.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(ddd) </I>Any final judgment for a fixed sum of money rendered by a New York Court having
jurisdiction under its own domestic laws in respect of any suit, action or proceeding against the
Company based upon this Agreement and the Deposit Agreement would be recognized and enforced
against the Company by Cayman Islands courts without re-examining the merits of the case under the
common law doctrine of obligation; <I>provided </I>that (i)&nbsp;adequate service of process has been effected
and the defendant has had a reasonable opportunity to be heard, (ii)&nbsp;such judgments or the
enforcement thereof are not contrary to the law, public policy, security or sovereignty of the
Cayman Islands, (iii)&nbsp;such judgments were not obtained by fraudulent means and do not conflict with
any other valid judgment in the same matter between the same parties, and (iv)&nbsp;an action between
the same parties in the same matter is not pending in any Cayman Islands court at the time the
lawsuit is instituted in the foreign court; it is not necessary that this Agreement, the Deposit
Agreement, the Prospectus or any other document be filed or recorded with any court or other
authority in the Cayman Islands or the PRC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(eee) </I>No holder of any of the Shares after the consummation of the transactions contemplated
by this Agreement and the Deposit Agreement is or will be subject to any personal liability in
respect of any liability of the Company solely by virtue of its holding of the Shares, and, except
as set forth in the Time of Sale Prospectus, there are no limitations on the rights of holders of
the Ordinary Shares or the ADSs to hold or vote their securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(fff) </I>Under the laws of the Cayman Islands, each holder of ADRs evidencing ADSs issued
pursuant to the Deposit Agreement shall be entitled, subject to the terms and provisions of the
Deposit Agreement, to seek enforcement of its rights through the Depositary or its nominee
registered as representative of the holders of the ADRs in a direct suit, action or proceeding
against the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(ggg) </I>The Company has not distributed, directly or indirectly, and, prior to the later to
occur of any delivery date and completion of the distribution of the Shares, will not distribute
any offering material in connection with the offering and sale of the Shares other than any
Prospectus or Time of Sale Prospectus to which the Representatives have consented in accordance
with this Agreement and any free writing prospectus set forth on Schedule&nbsp;III hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(hhh) </I>Except as set forth in the Time of Sale Prospectus, none of the Company or any of its
subsidiaries is engaged in any trading activities involving credit default swaps, commodity
contracts or other trading contracts which are not
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 18 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">currently traded on a securities or commodities
exchange and for which the market value cannot be determined.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(iii)&nbsp;</I>The Company has taken all reasonable steps to comply with, and has used reasonable
efforts to cause all of the Company&#146;s shareholders who are PRC residents or PRC citizens to comply
with, any applicable rules and regulations of the State Administration of Foreign Exchange (the
&#147;<B>SAFE Rules and Regulations</B>&#148;), including without limitation, requesting that each shareholder named
in the Company&#146;s share register that is, or is directly or indirectly owned or controlled by, a PRC
resident or PRC citizen to complete any registration and other procedures required under applicable
SAFE Rules and Regulations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(jjj) </I>The Company is aware of, and has been advised as to, the content of the Rules on Mergers
and Acquisitions of Domestic Enterprises by Foreign Investors jointly promulgated by the Ministry
of Commerce, the State Assets Supervision and Administration Commission, the State Tax
Administration, the State Administration of Industry and Commerce, the China Securities Regulatory
Commission (&#147;<B>CSRC</B>&#148;) and the State Administration of Foreign Exchange of the PRC on August&nbsp;8, 2006
(the &#147;<B>M&#038;A Rules</B>&#148;), in particular the relevant provisions thereof which purport to require offshore
special purpose vehicles (&#147;<B>SPVs</B>&#148;) formed for listing purposes and controlled directly or indirectly
by PRC companies or individuals, to obtain the approval of the CSRC prior to the listing and
trading of their securities on any stock exchange located outside of the PRC; the Company has
received legal advice specifically with respect to the M&#038;A Rules from its PRC counsel and the
Company understands such legal advice; and the Company has fully communicated such legal advice
from its PRC counsel to each of its directors and officers that signed the Registration Statement
and each such director and officer has confirmed that he or she understands such legal advice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(kkk) </I>The issuance and sale of the ADSs, the listing and trading of the ADSs on the NYSE or
the consummation of the transactions contemplated by this Agreement and the Deposit Agreement is
not and will not be, as of the date hereof or at the Closing and an Option Closing Date, if any,
adversely affected by the M&#038;A Rules or any official clarifications, guidance, interpretations or
implementation rules in connection with or related to the M&#038;A Rules, including the guidance and
notices issued by the CSRC on September&nbsp;8, 2006 and September&nbsp;21, 2006.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(lll) </I>Any certificate signed by an officer or director of the Company and delivered to the
Representatives or counsel for the Representatives as required or contemplated by Section 6(b)
hereof or the Deposit Agreement shall constitute a representation and warranty hereunder by the
Company, as to matters covered thereby or as excluded from or disclosed against therein, to each
Underwriter.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 19 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.<I>&nbsp;Representations and Warranties of the Selling Shareholders. </I>Each Selling Shareholder
represents and warrants to and agrees with each of the Underwriters that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(a)&nbsp;</I>Such Selling Shareholder, if an entity, has been duly organized and is validly existing
and in good standing as an entity in its jurisdiction of formation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(b)&nbsp;</I>This Agreement has been duly authorized, executed and delivered by each Selling
Shareholder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(c)&nbsp;</I>Such Selling Shareholder has, and on the Closing Date will have, valid and unencumbered
title to the Shares to be delivered by such Selling Shareholder on the Closing Date and full right,
power and authority to enter into this Agreement and to sell, assign, transfer and deliver the
Ordinary Shares underlying the Shares to be delivered by such Selling Shareholder on such Closing
Date hereunder; and upon the delivery of and payment for the Shares on the Closing Date hereunder
the several Underwriters will acquire valid and unencumbered title to the Shares to be delivered
by such Selling Shareholder on such Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(d)&nbsp;</I>The Ordinary Shares represented by the Shares to be sold by such Selling Shareholder may
be freely deposited by such Selling Shareholder with the Depositary or with Jianyu Yang (the
&#147;Selling Shareholder Custodian&#148;) as agent for the Depositary in accordance with the Deposit
Agreement against the issuance of ADRs evidencing the Shares representing such Ordinary Shares so
deposited by such Selling Shareholder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(e)&nbsp;</I>The execution and delivery by such Selling Shareholder of, and the performance by such
Selling Shareholder of its obligations under, this Agreement, the Custody Agreement signed by such
Selling Stockholder and the Company, as
custodian (in such capacity, the &#147;<B>Selling Shareholder Custodian</B>&#148;), relating to the deposit of
the Shares to be sold by such Selling Shareholder (the &#147;<B>Custody Agreement</B>&#148;), and the Power of
Attorney appointing certain individuals as such Selling Shareholder&#146;s attorneys-in-fact to the
extent set forth therein, relating to the transactions contemplated hereby and by the Registration
Statement (the &#147;<B>Power of Attorney</B>&#148;) will not contravene any provision of applicable law, or the
organizational documents of such Selling Shareholder (if such Selling Shareholder is an entity), or
any agreement or other instrument binding upon such Selling Shareholder or any judgment, order or
decree of any governmental body, agency or court having jurisdiction over such Selling Shareholder,
and no Governmental Authorization of any Government Agency is required for the performance by such
Selling Shareholder of its obligations under this Agreement or the Custody Agreement or Power of
Attorney of such Selling Shareholder,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 20 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">except such as may be required by the securities or Blue Sky
laws of the various states in connection with the offer and sale of the Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(f)&nbsp;</I>The Custody Agreement and the Power of Attorney have been duly authorized, executed and
delivered by such Selling Shareholder and are valid and binding agreements of such Selling
Shareholder enforceable in accordance with their terms, subject to bankruptcy, insolvency,
fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating
to or affecting creditors&#146; rights and to general equity principles.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(g)&nbsp;</I>The statements in the sections entitled &#147;Principal and Selling Shareholders&#148; relating to
such Selling Shareholder in the Prospectus and the Time of Sale Prospectus did not and do not
include any untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances under which they were made, not
misleading.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(h)&nbsp;</I>The sale of the Shares by such Selling Shareholder pursuant to this Agreement is not
prompted by any material information concerning the Company or any of its subsidiaries that is not
set forth the Time of Sale Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(i)&nbsp;</I>Except as disclosed in the Time of Sale Prospectus, there are no contracts, agreements or
understandings between the Selling Shareholder and any person that would give rise to a valid claim
against such Selling Shareholder or any Underwriter for a brokerage commission, finder&#146;s fee or
other like payment in connection with this offering.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(j)&nbsp;</I>Such Selling Shareholder has not taken, directly or indirectly, any action that is
designed to or that has constituted or that would reasonably be expected to cause or result in the
stabilization or manipulation of the price of any security of the Company to facilitate the sale or
resale of the Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(k)&nbsp;</I>Upon payment for the Shares sold by such Selling Shareholder under this Agreement and the
delivery by such Selling Shareholder to DTC (as
defined below) or its agent of the Shares in book entry form to a securities account
maintained by the Underwriters at DTC or its nominee, and payment therefor in accordance with this
Agreement, the Underwriters will acquire a securities entitlement (within the meaning of Section
8-501 of the Uniform Commercial Code (the &#147;<B>UCC</B>&#148;)) with respect to such Shares, and no action based
on an &#147;adverse claim&#148; (as defined in UCC Section&nbsp;8-102) may be asserted against the Underwriters
with respect to such security entitlement if, at such time, the Underwriters do not have notice of
any adverse claim within the meaning of UCC Section&nbsp;8-105.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(l)&nbsp;</I>The questionnaire containing certain information regarding such Selling Shareholder and
the election form which sets forth the amount of Ordinary
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 21 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Shares such Selling Shareholder has
elected to sell in the offering of the Shares (the &#147;<B>Questionnaire and Election Form</B>&#148;), completed by
such Selling Shareholder and submitted to the Company on or before the date hereof does not and as
of the Closing Date will not contain any untrue statement of material fact nor does it omit to
state any material fact required to be stated therein or necessary to make the statements therein
not misleading and such Selling Shareholder&#146;s election to sell the number of Ordinary Shares
indicated in the Questionnaire and Election Form is valid and binding on such Selling Shareholder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(m)&nbsp;</I>Except as disclosed in the Time of Sale Prospectus or the Questionnaire and Election Form,
such Selling Shareholder has no affiliations or associations with any member of the FINRA; and none
of the proceeds received by such Selling Shareholder from the sale of the Shares to be sold by such
Selling Shareholder hereunder will be paid to a member of the FINRA or any affiliate (or person
&#147;associated with,&#148; as such terms are used in the rules of the FINRA).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(n)&nbsp;</I>No transaction, stamp, capital or other issuance, registration, transaction, transfer or
withholding taxes or duties are payable by or on behalf of the Underwriters in connection with (i)
the sale and delivery of the Ordinary Shares represented by the Shares by such Selling Shareholder,
the issuance of such Shares by the Depositary, and the delivery of such Shares to or for the
account of the Underwriters, (ii)&nbsp;the purchase from such Selling Shareholder and the initial sale
and delivery by the Underwriters of the Shares to purchasers thereof, (iii)&nbsp;the deposit by such
Selling Shareholder of the Ordinary Shares with the Depositary and the Selling Shareholder
Custodian and the issuance and delivery of the ADRs evidencing the ADSs, or (iv)&nbsp;the execution and
delivery of this Agreement, the Power of Attorney and the Custody Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(o)&nbsp;</I>Such Selling Shareholder has not distributed and will not distribute, prior to the later
of the latest Closing Date and the completion of the Underwriters&#146; distribution of the Shares, any
offering material in connection with the offering and sale of the Shares by such Selling
Shareholders, including any free writing prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(p)&nbsp;</I>Other than as disclosed in the Time of Sale Prospectus, such Selling Shareholder does not
have any registration or other similar rights to have any equity or debt securities registered for
sale by the Company under the Registration Statement or included in the offering of the Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(q)&nbsp;</I>Such Selling Shareholder does not have, or has waived prior to the date hereof, any
preemptive right, co-sale right or right of first refusal or other similar right to purchase any of
the Ordinary Shares that are to be sold by the Company or any other Selling Shareholder to the
Underwriters pursuant to this Agreement; and such Selling Shareholder does not own any warrants,
options or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 22 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">similar rights to acquire, and does not have any right or arrangement to acquire, any
capital shares, right, warrants, options or other securities from the Company, other than those
described in the Prospectus and the Time of Sale Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(r)&nbsp;</I>The sale of the Ordinary Shares by such Selling Shareholder does not violate such Selling
Shareholder&#146;s internal policies regarding the sale of shares by its affiliates, if applicable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(s)&nbsp;</I>Such Selling Shareholder has no reason to believe that the representations and warranties
of the Company contained in Section&nbsp;1 are not true and correct, is familiar with the Registration
Statement, the Time of Sale Prospectus and the Prospectus and has no knowledge of any material
fact, condition or information not disclosed in the Time of Sale Prospectus or the Prospectus that
has had, or may have, a material adverse effect on the Company and its subsidiaries, taken as a
whole. Such Selling Shareholder is not prompted by any information concerning the Company or its
subsidiaries which is not set forth in the Time of Sale Prospectus to sell its Shares pursuant to
this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(t)&nbsp;</I>(i)&nbsp;The Registration Statement, as it relates to such Selling Shareholder, when it became
effective, did not contain and, as amended or supplemented, if applicable, will not contain any
untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein not misleading, (ii)&nbsp;the Time of Sale Prospectus, as it
relates to such Selling Shareholder, does not, and at the time of each sale of the Shares in
connection with the offering when the Prospectus is not yet available to prospective purchasers and
at the Closing Date (as defined in Section&nbsp;5), the Time of Sale Prospectus, as then amended or
supplemented by the Company, if applicable, as it relates to such Selling Shareholder, will not,
contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements therein, in the light of the circumstances under which they were made, not
misleading, (iii)&nbsp;each broadly available road show, if any, when considered together with the Time
of Sale Prospectus, as it relates to such Selling Shareholder, does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading and (iv)&nbsp;the
Prospectus, as it relates to such Selling Shareholder, does not contain and, as amended or
supplemented, if applicable, will not contain any untrue statement of
a material fact or omit to state a material fact necessary to make the statements therein, in
the light of the circumstances under which they were made, not misleading.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(u)&nbsp;</I>The choice of law set forth in Section&nbsp;17 hereof as the governing law of this Agreement is
a valid choice of law and will be recognized and given effect to in any action brought before a
court of competent jurisdiction in jurisdiction in which such Selling Shareholder is organized and
has its principal
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 23 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">place of business if not a natural person or in the jurisdiction in which such
person resides if a natural person. The courts of any such jurisdiction will recognize as a valid
judgment, a final and conclusive judgment in personam obtained in U.S. courts against such Selling
Shareholder based upon this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(v)&nbsp;</I>Neither such Selling Shareholder nor its properties, assets or revenues has any right of
immunity under Cayman Islands, PRC, Hong Kong or New York law, from any legal action, suit or
proceeding, from the giving of any relief in any such legal action, suit or proceeding, from
set-off or counterclaim, from the jurisdiction of any Cayman Islands, PRC, Hong Kong, New York or
U.S. federal court, from service of process, attachment upon or prior to judgment, or attachment in
aid of execution of judgment, or from execution of a judgment, or other legal process or proceeding
for the giving of any relief or for the enforcement of a judgment, in any such court, with respect
to its obligations, liabilities or any other matter under or arising out of or in connection with
this Agreement, the Power of Attorney and the Custody Agreement, and, to the extent that such
Selling Shareholder or any of its properties, assets or revenues may have or may hereafter become
entitled to any such right of immunity in any such court in which proceedings may at any time be
commenced, such Selling Shareholder waives or will waive such right to the extent permitted by law
and has consented to such relief and enforcement as provided in Section&nbsp;17 hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(w)&nbsp;</I>Any Selling Shareholder Certificate (as defined below) signed by any officer or director
of such Selling Shareholder and delivered to the Representatives or counsel for the Representatives
as required or contemplated by this Agreement shall constitute a representation and warranty
hereunder by such Selling Shareholder, as to matters covered thereby, to each Underwriter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<I>Agreements to Sell and Purchase. </I>The Company hereby agrees to sell to the several
Underwriters, and each Underwriter, upon the basis of the representations and warranties herein
contained, but subject to the conditions hereinafter stated, agrees, severally and not jointly, to
purchase from the Company at U.S.$&#091;<B>&#149;</B>&#093; per ADS (the &#147;<B>Purchase Price</B>&#148;) the respective number of Firm
Shares set forth in Schedule&nbsp;II hereto opposite the name of such Underwriter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On the basis of the representations and warranties contained in this Agreement, and subject to
its terms and conditions, the Selling Shareholders, severally and not jointly, hereby agree to sell
to the several Underwriters the
Additional Shares, and the Underwriters shall have the right to purchase, severally and not
jointly, up to an aggregate of &#091;1,800,000&#093; Additional Shares at the Purchase Price. You may
exercise this right on behalf of the Underwriters in whole or from time to time in part by giving
written notice to the Company and the Selling Shareholders not later than 30&nbsp;days after the date of
this Agreement. Any exercise notice shall specify the number of Additional Shares to be
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 24 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">purchased
by the Underwriters and the date on which such Shares are to be purchased. Each purchase date must
be at least one business day after the written notice is given and may not be earlier than the
closing date for the Firm Shares or later than ten business days after the date of such notice.
Additional Shares may be purchased as provided in Section&nbsp;5 hereof solely for the purpose of
covering over-allotments made in connection with the offering of the Firm Shares. On each day, if
any, that Additional Shares are to be purchased (an &#147;<B>Option Closing Date</B>&#148;), each Underwriter
agrees, severally and not jointly, to purchase from each Selling Shareholder the number of
Additional Shares (subject to such adjustments to eliminate fractional shares as you may determine)
that bears the same proportion to the total number of Additional Shares to be purchased from each
Selling Shareholder on such Option Closing Date as the number of Firm Shares set forth in Schedule
II hereto opposite the name of such Underwriter bears to the total number of Firm Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Seller hereby agrees that, without the prior written consent of the Representatives on
behalf of the Underwriters, it will not, during the period ending 180&nbsp;days after the date of the
Prospectus, (1)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or
otherwise transfer or dispose of, directly or indirectly, any Ordinary Shares, ADSs or any
securities convertible into or exercisable or exchangeable for Ordinary Shares or ADSs or (2)&nbsp;enter
into any swap or other arrangement that transfers to another, in whole or in part, any of the
economic consequences of ownership of Ordinary Shares or ADSs, whether any such transaction
described in clause (1)&nbsp;or (2)&nbsp;above is to be settled by delivery of Ordinary Shares, ADSs or such
other securities, in cash or otherwise or (3)&nbsp;file any registration statement with the Commission
relating to the offering of any Ordinary Shares, ADSs or any securities convertible into or
exercisable or exchangeable for Ordinary Shares or ADSs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The restrictions contained in the preceding paragraph shall not apply to (a)the Shares to be
sold hereunder, (b)&nbsp;transactions relating to Ordinary Shares, ADSs or other securities acquired in
open market transactions after the completion of the offering of the Shares, <I>provided </I>that no
filing under Section 16(a) of the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;),
shall be required or shall be voluntarily made in connection with subsequent sales of Ordinary
Shares or other securities acquired in such open market transactions, (c)&nbsp;the exercise of any
rights to acquire Ordinary Shares, ADSs or other securities of the Company issued pursuant to any
share option or similar equity incentive or compensation plan of the Company for the issuance of
share options or equity grants that is in effect as of the date of and disclosed in the Prospectus
(it being
understood that any subsequent sale, transfer or disposition of any securities of the Company
issued upon exercise of such options or grants shall be subject to the restrictions set forth in
this Section&nbsp;3), (d)&nbsp;transfers of Ordinary Shares or ADSs to shareholders who are existing
shareholders of the Company
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 25 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">prior to the date of the Prospectus or partners, members, stockholders
or affiliates of such shareholders, (e)&nbsp;transfers of Ordinary Shares, ADSs or any security
convertible into Ordinary Shares or ADSs (i)&nbsp;to an immediate family member or a trust formed for
the benefit of an immediate family member, (ii)&nbsp;as a bona fide gift or (iii)&nbsp;through will or
intestacy, (f)&nbsp;transfers or distributions of Ordinary Shares, ADSs or any security convertible into
Ordinary Shares or ADSs to partners, members, stockholders or affiliates of any Selling
Shareholder, <I>provided </I>that in the case of any transfer or distribution pursuant to clause (d), (e)
or (f), (x)&nbsp;each transferee, donee or distributee shall enter into a written agreement accepting
the restrictions set forth in this Section&nbsp;3 and (y)&nbsp;no filing under Section 16(a) of the Exchange
Act, reporting a reduction in beneficial ownership of Ordinary Shares or ADSs, shall be required or
shall be voluntarily made in respect of the transfer or distribution during the 180-day restricted
period, or (g)&nbsp;the establishment of a trading plan pursuant to Rule&nbsp;10b5-1 under the Exchange Act
for the transfer of Ordinary Shares or ADSs, <I>provided </I>that such plan does not provide for the
transfer of Ordinary Shares during the 180-day restricted period. In addition, each Selling
Shareholder, agrees that, without the prior written consent of the Representatives on behalf of the
Underwriters, it will not, during the period ending 180&nbsp;days after the date of the Prospectus, make
any demand for, or exercise any right with respect to, the registration of any Ordinary Shares,
ADSs or any security convertible into or exercisable or exchangeable for Ordinary Shares or ADSs.
Each Selling Shareholder consents to the entry of stop transfer instructions with the Company&#146;s
transfer agent and registrar against the transfer of any Ordinary Shares held by such Selling
Shareholder except in compliance with the foregoing restrictions. Notwithstanding the foregoing,
if (1)&nbsp;during the last 17&nbsp;days of the 180-day restricted period the Company issues an earnings
release or material news or a material event relating to the Company occurs; or (2)&nbsp;prior to the
expiration of the 180-day restricted period, the Company announces that it will release earnings
results during the 16-day period beginning on the last day of the 180-day period, the restrictions
imposed by this agreement shall continue to apply until the expiration of the 18-day period
beginning on the issuance of the earnings release or the occurrence of the material news or
material event, unless the Representatives waive, in writing, such extension. The Company shall
promptly notify the Representatives of any earnings release, news or event that may give rise to an
extension of the initial 180-day restricted period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<I>Terms of Public Offering</I>. The Company is advised by you that the Underwriters propose to
make a public offering of their respective portions of the Shares as soon after the Registration
Statement and this Agreement have become effective as in your judgment is advisable. The Company
is further advised by you that the Shares are to be offered to the public initially at U.S.$&#091;<B>&#149;</B>&#093; per
ADS (the &#147;<B>Public Offering Price</B>&#148;) and to certain dealers selected by you at a price that represents
a concession not in excess of U.S.$&#091;<B>&#149;</B>&#093; per ADS under the Public
Offering Price, and that any Underwriter may
allow, and such dealers may
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 26 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">reallow, a
concession, not in excess of U.S.$&#091;<B>&#149;</B>&#093; per ADS, to any Underwriter or to certain other dealers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<I>Payment and Delivery. </I>Executed transfer forms for the Ordinary Shares represented by the
Shares to be sold by the Selling Shareholders hereunder have been placed in custody, for delivery
under this Agreement, under Custody Agreements made with the Selling Shareholder Custodian. Each
Selling Shareholder agrees that the Ordinary Shares represented by the transfer forms held in
custody for the Selling Shareholders under such Custody Agreements are subject to the interests of
the Underwriters hereunder, that the arrangements made by the Selling Shareholders for such custody
are to that extent irrevocable, and that the obligations of the Selling Shareholders hereunder
shall not be terminated by operation of law, whether by the death of any individual Selling
Shareholder or the occurrence of any other event, or in the case of a trust, by the death of any
trustee or trustees or the termination of such trust. If any individual Selling Shareholder or any
such trustee or trustees should die, or if any other such event should occur, or if any of such
trusts should terminate, before the delivery of the Shares hereunder, such Shares shall be
delivered by the Selling Shareholder Custodian in accordance with the terms and conditions of this
Agreement as if such death or other event or termination had not occurred, regardless of whether or
not the Selling Shareholder Custodian shall have received notice of such death or other event or
termination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company will deliver the Firm Shares to or as instructed by the Representatives for the
accounts of the several Underwriters through the facilities of The Depository Trust Company (&#147;<B>DTC</B>&#148;)
in a form reasonably acceptable to the Representatives against payment of the purchase price in
Federal (same day) funds by official bank check or checks or wire transfer to an account at a bank
acceptable to the Representatives drawn to the order of the Company at the office of O&#146;Melveny &#038;
Myers LLP, Yin Tai Center, Office Tower, 37<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Floor, No.&nbsp;2 Jianguomenwai Avenue, Chao
Yang District, Beijing, 100022 PRC at 10:00&nbsp;a.m., New York time, on December &#091;<B>&#149;</B>&#093;, 2009, or at such
other time on the same or such other date, not later than December &#091;<B>&#149;</B>&#093;, 2009, as shall be
designated in writing by you. The time and date of such payment are hereinafter referred to as the
&#147;<B>First Closing Date</B>&#148; (the First Closing Date and each Option Closing Date, if any, being sometimes
referred to as a &#147;<B>Closing Date</B>&#148;). For purposes of Rule&nbsp;15c6-1 under the Exchange Act, the First
Closing Date (if later than the otherwise applicable settlement date) shall be the settlement date
for payment of funds and delivery of securities for all the Shares sold pursuant to the offering.
The ADRs evidencing the Firm Shares will be in definitive form, in such denominations and
registered in such names as the Representatives request. The ADRs will be made available for
checking and packaging at the above office or such other place designated by the Representatives at
least 24 hours prior to the First Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Selling Shareholder Custodian will deliver any Additional Shares to or as instructed by
the Representatives for the accounts of the several
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 27 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Underwriters through the facilities of DTC in a
form reasonably acceptable to the
Representatives against payment of the purchase price in Federal (same day) funds by wire
transfer to an account at a bank acceptable to the Representatives drawn to the order of the
Company for each Selling Shareholder at the office of O&#146;Melveny &#038; Myers LLP, Yin Tai Center, Office
Tower, 37<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Floor, No.&nbsp;2 Jianguomenwai Avenue, Chao Yang District, Beijing, 100022 PRC
at 10:00&nbsp;a.m., New York time, on the date specified in the corresponding notice described in
Section&nbsp;3, or at such other time on the same or such other date, no later than January &#091;<B>&#149;</B>&#093;, 2009,
as shall be designated in writing by you. The ADRs evidencing the Additional Shares will be in
definitive form, in such denominations and registered in such names as the Representatives request.
The ADRs will be made available for checking and packaging at the above office or such other place
designated by the Representatives at least 24 hours prior to the Option Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Firm Shares and Additional Shares shall be registered in such names and in such
denominations as you shall request in writing not later than one full business day prior to the
Closing Date or the applicable Option Closing Date, as the case may be. The Firm Shares and
Additional Shares shall be delivered to you on the Closing Date or an Option Closing Date, as the
case may be, for the respective accounts of the several Underwriters, with any transfer taxes
payable in connection with the transfer of the Shares to the Underwriters duly paid, against
payment of the Purchase Price therefor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<I>Conditions to the Underwriters&#146; Obligations</I>. The obligations of the Company and the
Selling Shareholders to sell the Shares to the Underwriters and the several obligations of the
Underwriters to purchase and pay for the Shares on the Closing Date are subject to the condition
that the Registration Statement shall have become effective not later than 4:00 p.m. (New York City
time) on the date hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The several obligations of the Underwriters are subject to the following further conditions:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(a)&nbsp;</I>Subsequent to the execution and delivery of this Agreement and prior to the Closing Date
there shall not have occurred any change, or any development involving a prospective change, in the
condition, financial or otherwise, or in the earnings, business or operations of the Company and
its subsidiaries, taken as a whole, from that set forth in the Time of Sale Prospectus as of the
date of this Agreement that, in your judgment, is material and adverse and that makes it, in your
judgment, impracticable to market the Shares on the terms and in the manner contemplated in the
Time of Sale Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(b)&nbsp;</I>The Representatives shall have received on the Closing Date a certificate, dated the
Closing Date and signed by an executive officer of the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 28 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company (the &#147;<B>Company Certificate</B>&#148;), to the
effect set forth in Section&nbsp;6(a)(i) above and to the effect that the representations and warranties
of the Company contained in this Agreement are true and correct as of the Closing Date and that
the Company has complied with all of the agreements and satisfied all of the conditions on its
part to be performed or satisfied hereunder on or before the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The officer signing and delivering such certificate may rely upon the best of his or her
knowledge as to proceedings threatened.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(c)&nbsp;</I>The Representatives shall have received a certificate, dated as of the Closing Date, of an
authorized representative of each Selling Shareholder (the &#147;<B>Selling Shareholder Certificate</B>&#148;) in
which such authorized representative shall state that the representations and warranties of such
Selling Shareholder in this Agreement are true and correct and the Selling Shareholders have
complied with all agreements and satisfied all conditions on their part to be performed or
satisfied hereunder at or prior to such Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(d)&nbsp;</I>The Representatives shall have received on the Closing Date an opinion of Simpson Thacher
&#038; Bartlett LLP, U.S. counsel for the Company, dated the Closing Date, addressed to the
Representatives, in form and substance reasonably satisfactory to the Representatives. In rendering
such opinion, Simpson Thacher &#038; Bartlett LLP may rely as to all matters governed by Cayman Islands
law on the opinion of Walkers referenced to below and all matters governed by PRC law upon the
opinion of Jingtian &#038; Gongcheng Attorneys at Law referenced to below.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(e)&nbsp;</I>The Representatives shall have received on the Closing Date an opinion of Walkers, Cayman
Islands counsel for the Company, dated as of the Closing Date, addressed to the Representatives, in
form and substance reasonably satisfactory to the Representatives.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(f)&nbsp;</I>The Representatives shall have received on the Closing Date, an opinion of Jingtian &#038;
Gongcheng Attorneys at Law, PRC counsel for the Company, dated as of the Closing Date, addressed to
the Representatives, in form and substance reasonably satisfactory to the Representatives.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(g)&nbsp;</I>The Representatives shall have received on the Closing Date, an opinion of Foo, Leung &#038;
Yeung, Solicitors, Hong Kong counsel for the Company, dated as of the Closing Date, addressed to
the Representatives, in form and substance reasonably satisfactory to the Representatives.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(h)&nbsp;</I>The Representatives shall have received on the Closing Date, an opinion of Walkers,
British Virgin Islands counsel for the Company, dated as of the Closing Date, addressed to the
Representatives, in form and substance reasonably satisfactory to the Representatives.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 29 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(i)&nbsp;</I>The Representatives shall have received on the Closing Date an opinion of Troutman Sanders
LLP, U.S. counsel for each Selling Shareholder, dated as of the Closing Date, addressed to the
Representatives, in form and substance reasonably satisfactory to the Representatives.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(j)&nbsp;</I>The Representatives shall have received on the Closing Date an opinion of Walkers, British
Virgin Islands counsel for each Selling Shareholder, dated as of the Closing Date, addressed to the
Representatives, in form and substance reasonably satisfactory to the Representatives.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(k)&nbsp;</I>The Representatives shall have received on the Closing Date an opinion of Paul, Hastings,
Janofsky &#038; Walker LLP, counsel to the Depositary, dated as of the Closing Date, addressed to the
Representatives, in form and substance reasonably satisfactory to the Representatives.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(l)&nbsp;</I>The Representatives shall have received on the Closing Date an opinion of O&#146;Melveny &#038;
Myers LLP, U.S. counsel to the Underwriters, dated as of the Closing Date, with respect to such
matters as the Underwriters may require, and the Company and the Selling Shareholders shall have
furnished to such counsel such documents, as they request for the purpose of enabling them to pass
upon such matters. In rendering such opinion, O&#146;Melveny &#038; Myers LLP may rely as to all matters
governed by Cayman Islands law on the opinion of Walkers referenced to above and all matters
governed by PRC law upon the opinion of Commerce &#038; Finance Law Offices referenced to below.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(m)&nbsp;</I>The Representatives shall have received on the Closing Date an opinion of Commerce &#038;
Finance Law Offices, PRC counsel to the Underwriters, dated as of the Closing Date, with respect to
such matters as the Underwriters may require, and the Company and the Selling Shareholders shall
have furnished to such counsel such documents, as they request for the purpose of enabling them to
pass upon such matters.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(n)&nbsp;</I>The Representatives shall have received, on each of the date hereof and the Closing Date,
a letter dated the date hereof or the Closing Date, as the case may be, in form and substance
satisfactory to the Underwriters, from Ernst &#038; Young Hua Ming, independent public accountants,
containing statements and information of the type ordinarily included in accountants&#146; &#147;comfort
letters&#148; to underwriters with respect to the financial statements and certain financial information
contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus; <I>provided</I>
that the letter delivered on the Closing Date shall use a &#147;cut-off date&#148; not earlier than three
days prior to the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(o)&nbsp;</I>The Representatives shall have received a certificate, dated as of the Closing Date,
signed by the Chief Financial Officer of the Company certifying
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->- 30 -<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">as to, among other things, the
accuracy of certain financial and operating data relating to the Company included in the Time of
Sale Prospectus.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(p)&nbsp;</I>The &#147;lock-up&#148; agreements, each substantially in the form of Exhibit&nbsp;A hereto (the &#147;<B>Lock-Up
Agreements</B>&#148;), between you and certain shareholders, officers and directors of the Company relating
to sales and certain other dispositions of Ordinary Shares or certain other securities, delivered
to you on or before the date hereof, shall be in full force and effect on the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(q)&nbsp;</I>The Depositary shall have furnished or caused to be furnished to the Underwriters a
certificate satisfactory to the Underwriters of one of its authorized officers with respect to the
deposit with it of the Ordinary Shares represented by the Shares against issuance of the ADRs
evidencing the Shares, the execution, issuance, countersignature and delivery of the ADRs
evidencing the Shares pursuant to the Deposit Agreement and such other matters related thereto as
the Underwriters may reasonably request.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(r)&nbsp;</I>The Company and the Depositary shall have executed and delivered the Deposit Agreement and
the Deposit Agreement shall be in full force and effect and the Company and the Depositary shall
have taken all action necessary to permit the deposit of the Ordinary Shares and the issuance of
the Shares in accordance with the Deposit Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(s)&nbsp;</I>The Custody Agreement shall have been executed by each of the Selling Shareholders or
Attorney-in-Fact on behalf of the Selling Shareholders on or prior to the date hereof and
certificates in negotiable form representing all of the Ordinary Shares to be sold by the Selling
Shareholders hereunder on the Closing Date shall have been placed in custody under the Custody
Agreement by each of the Selling Shareholders, duly executed and delivered by such Selling
Shareholders to the Custodian, on or prior to the date at least two business days prior to the
Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(t)&nbsp;</I>On or prior to the Closing Date, the Underwriters shall have received from the Custodian
U.S. Treasury Department Form W-9 or the applicable Form W-8 (or other applicable form or statement
specified by Treasury Department regulations in lieu thereof) properly completed and executed by
each Selling Shareholder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(u)&nbsp;</I>The Shares shall have been approved for listing on the NYSE.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(v)&nbsp;</I>On or prior to the Closing Date, the Shares shall be eligible for clearance and settlement
through the facilities of DTC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(w)&nbsp;</I>No Prospectus or Time of Sale Prospectus or amendment or supplement to the Registration
Statement, the ADS Registration Statement or the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 31 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Prospectus shall have been filed to which the
Representatives shall have objected in writing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(x)&nbsp;</I>The FINRA shall have confirmed that it has not raised any objection with respect to the
fairness and reasonableness of the underwriting terms and arrangements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The several obligations of the Underwriters to purchase Additional Shares hereunder are
subject to the delivery to you on the applicable Option Closing Date of such documents as you may
reasonably request with respect to the good standing of the Company, the due authorization and
issuance of the Additional
Shares to be sold on such Option Closing Date and other matters related to the issuance of
such Additional Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.<I>&nbsp;Covenants of the Company</I>. The Company covenants with each Underwriter as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(a)&nbsp;</I>To furnish to you, without charge, four signed copies of the Registration Statement
(including exhibits thereto) and for delivery to each other Underwriter a conformed copy of the
Registration Statement (without exhibits thereto) and to furnish to you in New York City, without
charge, prior to 10:00&nbsp;a.m. New York City time on the business day next succeeding the date of this
Agreement and during the period mentioned in Section&nbsp;7(e) or 7(f) below, as many copies of the Time
of Sale Prospectus, the Prospectus and any supplements and amendments thereto or to the
Registration Statement as you may reasonably request.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(b)&nbsp;</I>Before amending or supplementing the Registration Statement, the ADS Registration
Statement, the Prospectus or the Time of Sale Prospectus, to furnish to you a copy of each such
proposed amendment or supplement and not to file any such proposed amendment or supplement to which
you reasonably object, and to file with the Commission within the applicable period specified in
Rule&nbsp;424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(c)&nbsp;</I>To furnish to you a copy of each proposed free writing prospectus to be prepared by or on
behalf of, used by, or referred to by the Company and not to use or refer to any proposed free
writing prospectus to which you reasonably object.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(d)&nbsp;</I>Not to take any action that would result in an Underwriter or the Company being required
to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing
prospectus prepared by or on behalf of the Underwriter that the Underwriter otherwise would not
have been required to file thereunder.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 32 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(e)&nbsp;</I>If the Time of Sale Prospectus is being used to solicit offers to buy the Shares at a time
when the Prospectus is not yet available to prospective purchasers and any event shall occur or
condition exist as a result of which it is necessary to amend or supplement the Time of Sale
Prospectus in order to make the statements therein, in the light of the circumstances, not
misleading, or if any event shall occur or condition exist as a result of which the Time of Sale
Prospectus conflicts with the information contained in the Registration Statement then on file, or
if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time
of Sale Prospectus to comply with applicable law, forthwith to prepare, file with the Commission
and furnish, at its own expense, to the Underwriters and to any dealer upon request, either
amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of
Sale Prospectus as so amended or supplemented will not, in the light of the circumstances when
the Time of Sale Prospectus is delivered to a prospective purchaser, be misleading or so that the
Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the Registration
Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with
applicable law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(f)&nbsp;</I>If, during such period after the first date of the public offering of the Shares as in the
opinion of counsel for the Underwriters the Prospectus (or in lieu thereof the notice referred to
in Rule 173(a) under the Securities Act) is required by law to be delivered in connection with
sales by an Underwriter or dealer, any event shall occur or condition exist as a result of which it
is necessary to amend or supplement the Prospectus in order to make the statements therein, in the
light of the circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule
173(a) under the Securities Act) is delivered to a purchaser, not misleading, or if, in the opinion
of counsel for the Underwriters, it is necessary to amend or supplement the Prospectus to comply
with applicable law, forthwith to prepare, file with the Commission and furnish, at its own
expense, to the Underwriters and to the dealers (whose names and addresses you will furnish to the
Company) to which Shares may have been sold by you on behalf of the Underwriters and to any other
dealers upon request, either amendments or supplements to the Prospectus so that the statements in
the Prospectus as so amended or supplemented will not, in the light of the circumstances when the
Prospectus (or in lieu thereof the notice referred to in Rule 173(a) under the Securities Act) is
delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will
comply with applicable law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(g)&nbsp;</I>To endeavor to qualify the Shares for offer and sale under the securities or Blue Sky laws
of such jurisdictions as you shall reasonably request.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(h)&nbsp;</I>To make generally available to the Company&#146;s security holders and to you as soon as
practicable an earning statement covering a period of at least twelve months beginning with the
first fiscal quarter of the Company
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 33 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">occurring after the date of this Agreement which shall satisfy
the provisions of Section&nbsp;11(a) of the Securities Act and the rules and regulations of the
Commission thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;To comply with all applicable securities and other laws, rules and regulations in each
jurisdiction in which the Directed Shares are offered in connection with the Directed Share
Program.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(j)&nbsp;</I>The Company will use the net proceeds received by it in connection with this offering in
the manner described in the &#147;Use of Proceeds&#148; section of the Time of Sale Prospectus and, except as
disclosed in the Time of Sale Prospectus, the Company does not intend to use any of the proceeds
from the sale of the Shares hereunder to repay any outstanding debt owed to any affiliate of any
Underwriter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(k)&nbsp;</I>The Company will not take, directly or indirectly, any action designed to or that would
constitute or that might reasonably be expected to cause or result in, stabilization or
manipulation of the price of any securities of the Company to facilitate the sale or resale of the
Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(l)&nbsp;</I>The Company will indemnify and hold harmless the Underwriters against any documentary,
stamp or similar issue tax, including any interest and penalties, on the creation, issue and sale
of the Shares and on the execution and delivery of this Agreement. All payments to be made by the
Company hereunder shall be made exclusive of Value Added Tax, Goods and Services Tax, Business Tax,
withholding tax and/or similar taxes (collectively, &#147;<B>Taxes</B>&#148;) and shall be made without withholding
or deduction for or on account of any present or future taxes, duties or governmental charges
whatsoever unless the Company is compelled by law to deduct or withhold such taxes, duties or
charges. In that event, the Company shall (i)&nbsp;pay such additional amounts as may be necessary in
order that the net amounts received after such withholding or deduction shall equal the amounts
that would have been received if no withholding or deduction had been made, and (ii)&nbsp;forward to the
Underwriters for their records an official receipt or a copy of the official receipt issued by the
taxing authority or other document evidencing payment of such taxes, duties or charges that the
Company was compelled by law to deduct or withhold and remit to the taxing authority to satisfy the
tax obligation of the Underwriters. The Company agrees that it shall be responsible for all Taxes
as well as all applicable compliance and regulatory obligations related to such Taxes which may
arise from or in connection with this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(m)&nbsp;</I>The Company will use its best efforts to maintain the listing of the Shares on the NYSE.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 34 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(n)&nbsp;</I>The Company, during the period when a prospectus (or, in lieu thereof, the notice referred
to in Rule 173(a) under the Securities Act) is required to be delivered under the Securities Act in
connection with the offer or sale of the Shares, will file all reports and other documents required
to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the
Exchange Act and the applicable rules and regulations of the Commission thereunder within the time
periods required thereby.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(o)&nbsp;</I>The Company shall comply with the SAFE Rules and Regulations, and shall use reasonable
efforts to cause its shareholders and option holders that are, or that are directly or indirectly
owned or controlled by, PRC residents or PRC citizens, to comply with the SAFE Rules and
Regulations applicable to them in connection with the Company, including without limitation,
requesting each shareholder and option holder, that is, or is directly or indirectly owned or
controlled by, a PRC resident or PRC citizen to complete any registration and other procedures
required under applicable SAFE Rules and Regulations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(p)&nbsp;</I>The Company shall at all times maintain transfer restrictions (including the inclusion of
legends in share certificates, as may be required) with respect to the Company&#146;s Ordinary Shares
which are subject to transfer restrictions pursuant to this Agreement and the Lock-Up Agreements
and shall ensure compliance with such restrictions on transfer of restricted Ordinary Shares. The
Company shall retain all share certificates which are by their terms subject to transfer
restrictions until such time as such transfer restrictions are no longer applicable to such
securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(q)&nbsp;</I>The Company will deposit the Ordinary Shares with the custodian for the Depositary in
compliance with the provisions of the Deposit Agreement and instruct the Depositary at the Closing
Date to deliver the ADR evidencing the ADSs representing such Ordinary Shares to participant
accounts within DTC in accordance with the written instructions of each of the Underwriters.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(r)&nbsp;</I>The Company agrees (i)&nbsp;not to attempt to avoid any judgment obtained by it or denied to it
in a court of competent jurisdiction outside of the Cayman Islands; (ii)&nbsp;following the consummation
of the offering of the Shares, it will use its best efforts to obtain and maintain all approvals,
if any, required in the Cayman Islands to pay and remit outside the Cayman Islands all dividends
declared by the Company and payable on the Ordinary Shares; and (iii)&nbsp;it will use its best efforts
to obtain and maintain all approvals, if any, required in the Cayman Islands for the Company to
acquire sufficient foreign exchange for the payment of dividends and all other relevant purposes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(s)&nbsp;</I>The Company will use its best efforts to comply with Sarbanes-Oxley, and will use its best
efforts to cause the Company&#146;s directors and officers, in their capacities as such, to comply with
Sarbanes-Oxley.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 35 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(t)&nbsp;</I>The Company will not directly or indirectly use the proceeds of the sale of the Shares
hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint
venture partner or other person or entity, for the purpose of financing the activities of any
person currently subject to any U.S. sanctions administered by OFAC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(u)&nbsp;</I>The Company will comply with Rule 433(d) (without reliance on Rule&nbsp;164(b)) and Rule 433(g)
under the Securities Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(v)&nbsp;</I>The Company will not, prior to the delivery of the Shares on the Closing Date, issue any
press release or other communication directly or indirectly and will hold no press conferences with
respect to the Company or any of its subsidiaries, the financial condition, results of operations,
business, properties, assets or liabilities of the Company or any of its subsidiaries, or the
offering or sale of the Shares, without the Underwriters&#146; prior consent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(w)&nbsp;</I>The Company will not, at any time at or after the execution of this Agreement, directly or
indirectly, offer or sell any Shares by means of any
&#147;prospectus&#148; (within the meaning of the Securities Act), or use any &#147;prospectus&#148; (within the
meaning of the Securities Act) in connection with the offer or sale of the Shares, in each case
other than the then most recent prospectus included in the Registration Statement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(x)&nbsp;</I>The Company will do and perform all things required to be done or performed under this
Agreement by the Company prior to the Closing Date and to satisfy all conditions precedent to the
delivery of the Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<I>Covenants of Selling Shareholders</I>. Each of the Selling Shareholders, severally and not
jointly, covenants with each Underwriter as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(a)&nbsp;</I>Such Selling Shareholder will indemnify and hold harmless the Underwriters against any
documentary, stamp or similar issue tax, including any interest and penalties, on the creation,
issue and sale of the Shares by such Selling Shareholder and on the execution and delivery of this
Agreement. All payments to be made by each Selling Shareholder hereunder shall be made exclusive of
any Taxes and shall be made without withholding or deduction for or on account of any present or
future taxes, duties or governmental charges whatsoever unless such Selling Shareholder or the
Company is compelled by law to deduct or withhold such taxes, duties or charges. In that event, a
Selling Shareholder shall (i)&nbsp;pay such additional amounts as may be necessary in order that the net
amounts received after such withholding or deduction shall equal the amounts that would have been
received if no withholding or deduction had been made, and (ii)&nbsp;forward to the Underwriters for
their records an official receipt of a copy of the official receipt issued by the taxing authority
or other document evidencing
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 36 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">payment of such taxes, duties or charges that such Selling Shareholder
was compelled by law to deduct or withhold and remit to the taxing authority to satisfy the tax
obligation of such Selling Shareholder. Such Selling Shareholder agrees that it shall be
responsible for all Taxes as well as all applicable compliance and regulatory obligations related
to such Taxes which may arise from or in connection with this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(b)&nbsp;</I>Such Selling Shareholder agrees to procure delivery to the Representatives on or prior to
the Closing Date of a properly completed and executed U.S. Treasury Department Form W-9 or
applicable Form W-8 (or other applicable form or statement specified by Treasury Department
regulations in lieu thereof).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(c)&nbsp;</I>The Shares to be sold by such Selling Shareholder hereunder are subject to the interest of
the Underwriters and the obligations of such Selling Shareholder hereunder shall not be terminated
by any act of such Selling Shareholder, by operation of law, by the death or incapacity of any
individual Selling Shareholder or, in the case of a trust, by the death or incapacity of any
executor or trustee or the termination of such trust, or the occurrence of any other event.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(d)&nbsp;</I>To notify promptly the Company and the Representatives if, at any time prior to the date
on which the distribution of the Shares as contemplated herein and in the Registration Statement
and the Prospectus has been completed, as determined by the Representatives, such Selling
Shareholder has knowledge of the occurrence of any event relating to such Selling Shareholder as a
result of which the Registration Statement and the Prospectus, in each case as then amended or
supplemented, would include an untrue statement of a material fact or omit to state any material
fact necessary to make the statements therein (except in the case of the Registration Statement),
in the light of the circumstances under which they were made not misleading.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(e)&nbsp;</I>Prior to the delivery of the Shares on the Closing Date, such Selling Shareholder will
deposit, or cause to be deposited on its behalf, Ordinary Shares with the Depositary in accordance
with the provisions of the Deposit Agreement and otherwise to comply with the Deposit Agreement so
that ADRs evidencing the ADSs will be executed (and, if applicable, countersigned) and issued by
the Depositary against receipt of the Ordinary Shares and delivered to the Underwriters.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(f)&nbsp;</I>Such Selling Shareholder will not (and will cause its affiliates not to) take, directly or
indirectly, any action which is designed to or which constitutes or which might reasonably be
expected to cause or result in stabilization or manipulation of the price of any securities of the
Company to facilitate the sale or resale of the Shares.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 37 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(g)&nbsp;</I>Such Selling Shareholder will advise the Representatives promptly and, if requested by the
Representatives, confirm such advice in writing, so long as a prospectus is required by the
Securities Act to be delivered (whether physically or through compliance with Rule&nbsp;172 under the
Securities Act or any similar rule) in connection with any sale of ADSs by the Selling Shareholder
hereunder, of (A)&nbsp;any material change in condition (financial or otherwise), results of operations,
business, general affairs, management, shareholders equity, properties or prospects of the Company
and its subsidiaries, which has come to the attention of such Selling Shareholder, (B)&nbsp;any change
in information contained in the Registration Statement, the Prospectus and the Time of Sale
Prospectus, if any, relating to such Selling Shareholder or (C)&nbsp;any new material information
relating to the Company or its subsidiaries or relating to any matter stated in the Registration
Statement, the Prospectus and the Time of Sale Prospectus, if any, which has come to the attention
of such Selling Shareholder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(h)&nbsp;</I>Such Selling Shareholder will cooperate to the extent necessary to cause the Registration
Statement or any post-effective amendment thereto to become effective at the earliest practical
time and to do and perform all things to be done and performed under this Agreement prior to the
Closing Date and to satisfy all conditions precedent of such Selling Shareholder to the delivery of
the Shares and the Shares to be sold by such Selling Shareholder pursuant to this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(i)&nbsp;</I>Such Selling Shareholder will not, directly or indirectly, use any of the proceeds it will
receive from the sale of the Shares contemplated hereby (A)&nbsp;to fund any operations in, to finance
any investments, projects or activities in, or to make any payments to, any country, or to make any
payments to, or finance any activities with, any Person, targeted by the Sanctions, or (B)&nbsp;in any
manner that is not in compliance with applicable laws, rules and regulations of any Governmental
Agency having jurisdiction over such Selling Shareholder, including, without limitation, the
requirement for PRC residents or citizens to repatriate the net proceeds received by such Selling
Shareholder into the PRC under the SAFE Rules and Regulations and applicable regulations of the PRC
Ministry of Commerce.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.<I>&nbsp;Expenses</I>. Whether or not the transactions contemplated in this Agreement are consummated
or this Agreement is terminated, the Sellers agree to pay or cause to be paid all expenses incident
to the performance of their obligations under this Agreement, including: (i)&nbsp;the fees,
disbursements and expenses of the Company&#146;s counsel, the Company&#146;s accountants and counsel for the
Selling Shareholders in connection with the registration and delivery of the Shares under the
Securities Act and all other fees or expenses in connection with the preparation and filing of the
Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, the Prospectus,
any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 38 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and
amendments and supplements to any of the foregoing, including all printing costs associated
therewith, and the mailing and delivering of copies thereof to the Underwriters and dealers, in the
quantities hereinabove specified, (ii)&nbsp;all costs and expenses related to the transfer and delivery
of the Shares to the Underwriters, including any transfer or other taxes payable thereon, (iii)&nbsp;the
cost of printing or producing any Blue Sky or Legal Investment memorandum in connection with the
offer and sale of the Shares under state securities laws and all expenses in connection with the
qualification of the Shares for offer and sale under state securities laws as provided in
Section&nbsp;8(g) hereof, including filing fees and the reasonable fees and disbursements of counsel
for the Underwriters in connection with such qualification and in connection with the Blue Sky or
Legal Investment memorandum, (iv)&nbsp;all filing fees and expenses incurred in connection with the review and qualification of the
offering of the Shares by the FINRA, (v)&nbsp;all fees and expenses in connection with the preparation
and filing of the registration statement on Form 8-A relating to the Ordinary Shares and all costs
and expenses incident to listing the Shares on the NYSE, (vi)&nbsp;the cost of printing certificates
representing the Shares, (vii)&nbsp;the costs and charges of any transfer agent, registrar or
depositary, (viii)&nbsp;the costs and expenses of the Company relating to investor presentations on any
&#147;road show&#148; undertaken in connection with the marketing of the offering of the Shares, including,
without limitation, expenses associated with the preparation or dissemination of any electronic
road show, expenses associated with the production of road show slides and graphics, fees and
expenses of any consultants engaged in connection with the road show presentations with the prior
approval of the Company, travel and lodging expenses of the representatives and officers of
the Company and any such consultants, and one-half the cost of any aircraft chartered in
connection with the road show, (ix)&nbsp;the document production charges and expenses associated with
printing this Agreement, (x)&nbsp;all fees and disbursements of counsel incurred by the Underwriters in
connection with the Directed Share Program and stamp duties, similar taxes or duties or other
taxes, if any, incurred by the Underwriters in connection with the Directed Share Program and (xi)
all other costs and expenses incident to the performance of the obligations of the Company
hereunder for which provision is not otherwise made in this Section. It is understood, however,
that except as provided in this Section, Section&nbsp;11 entitled &#147;Indemnity and Contribution&#148;,
Section&nbsp;12 entitled &#147;Directed Share Program Indemnification&#148; and the last paragraph of Section&nbsp;14
below, the Underwriters will pay all of their costs and expenses, including fees and disbursements
of their counsel, stock transfer taxes payable on resale of any of the Shares by them and any
advertising expenses connected with any offers they may make, which costs and expenses shall be
apportioned among the Underwriters based on the relative economic benefits received by the
Underwriters under this Agreement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 39 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The provisions of this Section shall not supersede or otherwise affect any agreement that the
Sellers may otherwise have for the allocation of such expenses among themselves.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.<I>&nbsp;Covenants of the Underwriters</I>. Each Underwriter severally covenants with the Company not
to take any action that would result in the Company being required to file with the Commission
under Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of
such Underwriter that otherwise would not be required to be filed by the Company thereunder, but
for the action of the Underwriter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.<I>&nbsp;Indemnity and Contribution. </I>(a)&nbsp;The Company agrees to indemnify and hold harmless each
Underwriter, each person, if any, who controls any Underwriter within the meaning of either
Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, and each affiliate of any
Underwriter within the meaning of Rule&nbsp;405 under the Securities Act from and against any and all
losses, claims, damages and liabilities (including, without limitation, any legal or other expenses
reasonably incurred in connection with defending or investigating any such action or claim) caused
by any untrue statement or alleged untrue statement of a material fact contained in the
Registration Statement or any amendment thereof, any preliminary prospectus, the Time of Sale
Prospectus, any issuer free writing prospectus as defined in Rule 433(h) under the Securities Act,
any Company information that the Company has filed, or is required to file, pursuant to Rule 433(d)
under the Securities Act, or the Prospectus or any amendment or supplement thereto, or caused by
any omission or alleged omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, except insofar as such losses, claims,
damages or liabilities are caused by any such untrue statement or omission or alleged untrue
statement or omission based upon information relating to any Underwriter
furnished to the Company in writing by such Underwriter through you expressly for use therein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(b)&nbsp;</I>The Selling Shareholders, severally and not jointly, agree to indemnify and hold harmless
each Underwriter, each person, if any, who controls any Underwriter within the meaning of either
Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, and each affiliate of any
Underwriter within the meaning of Rule&nbsp;405 under the Securities Act from and against any and all
losses, claims, damages and liabilities (including, without limitation, any legal or other expenses
reasonably incurred in connection with defending or investigating any such action or claim) caused
by any untrue statement or alleged untrue statement of a material fact contained in the
Registration Statement or any amendment thereof, any preliminary prospectus, the Time of Sale
Prospectus, any issuer free writing prospectus as defined in Rule 433(h) under the Securities Act,
any Company information that the Company has filed, or is required to file, pursuant to Rule 433(d)
under the Securities Act, or the Prospectus or any amendment or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 40 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">supplement thereto, or caused by
any omission or alleged omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, but in any case only with reference to
information relating to such Selling Shareholder furnished in writing by or on behalf of such
Selling Shareholder expressly for use in the Registration Statement or any amendment thereof, any
preliminary prospectus, the Time of Sale Prospectus, any issuer free writing prospectus as defined
in Rule 433(h) under the Securities Act, any Company information that the Company has filed, or is
required to file, pursuant to Rule 433(d) of the Securities Act, or the Prospectus or any amendment
or supplement thereto. The liability of each Selling Shareholder under the indemnity agreement
contained in this paragraph shall be limited to the net proceeds received by it from the sale of
Additional Shares under this Agreement, if any.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(c)&nbsp;</I>Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the
Company, the Selling Shareholders, the directors of the Company, the officers of the Company who
sign the Registration Statement and each person, if any, who controls the Company or any Selling
Shareholder within the meaning of either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the
Exchange Act from and against any and all losses, claims, damages and liabilities (including,
without limitation, any legal or other expenses reasonably incurred in connection with defending or
investigating any such action or claim) caused by any untrue statement or alleged untrue statement
of a material fact contained in the Registration Statement or any amendment thereof, any
preliminary prospectus, the Time of Sale Prospectus, any issuer free writing prospectus as defined
in Rule 433(h) under the Securities Act, any Company information that the Company has filed, or is
required to file, pursuant to Rule 433(d) under the Securities Act, or the Prospectus (as amended
or supplemented if the Company shall have furnished any amendments or supplements thereto), or
caused by any omission or alleged omission to state therein a material fact required to be stated
therein or necessary to make the statements therein not misleading, but only with reference to
information relating to such Underwriter furnished to the Company in
writing by such Underwriter through you expressly for use in the Registration Statement, any
preliminary prospectus, the Time of Sale Prospectus, any issuer free writing prospectus or the
Prospectus or any amendment or supplement thereto, it being understood and agree that the only such
information furnished by any Underwriter consists of the following information in the Prospectus
furnished on behalf of each Underwriter: the paragraph relating to stabilization by the
Underwriters appearing under the caption &#147;Underwriting.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(d)&nbsp;</I>In case any proceeding (including any governmental investigation) shall be instituted
involving any person in respect of which indemnity may be sought pursuant to Section&nbsp;11(a), 11(b)
or 11(c), such person (the &#147;<B>indemnified party</B>&#148;) shall promptly notify the person against whom such
indemnity may be sought (the &#147;<B>indemnifying party</B>&#148;) in writing and the indemnifying party, upon
request of the indemnified party, shall retain counsel reasonably satisfactory to the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 41 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">indemnified
party to represent the indemnified party and any others the indemnifying party may designate in
such proceeding and shall pay the fees and disbursements of such counsel related to such
proceeding. In any such proceeding, any indemnified party shall have the right to retain its own
counsel, but the fees and expenses of such counsel shall be at the expense of such indemnified
party unless (i)&nbsp;the indemnifying party and the indemnified party shall have mutually agreed to the
retention of such counsel or (ii)&nbsp;the named parties to any such proceeding (including any impleaded
parties) include both the indemnifying party and the indemnified party and representation of both
parties by the same counsel would be inappropriate due to actual or potential differing interests
between them. It is understood that the indemnifying party shall not, in respect of the legal
expenses of any indemnified party in connection with any proceeding or related proceedings in the
same jurisdiction, be liable for (i)&nbsp;the fees and expenses of more than one separate firm (in
addition to any local counsel) for all Underwriters and all persons, if any, who control any
Underwriter within the meaning of either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the
Exchange Act or who are affiliates of any Underwriter within the meaning of Rule&nbsp;405 under the
Securities Act, (ii)&nbsp;the fees and expenses of more than one separate firm (in addition to any local
counsel) for the Company, its directors, its officers who sign the Registration Statement and each
person, if any, who controls the Company within the meaning of either such Section and (iii)&nbsp;the
fees and expenses of more than one separate firm (in addition to any local counsel) for all Selling
Shareholders and all persons, if any, who control any Selling Shareholder within the meaning of
either such Section, and that all such fees and expenses shall be reimbursed as they are incurred.
In the case of any such separate firm for the Underwriters and such control persons and affiliates
of any Underwriters, such firm shall be designated in writing by Morgan Stanley. In the case of
any such separate firm for the Company, and such directors, officers and control persons of the
Company, such firm shall be designated in writing by the Company. In the case of any such separate
firm for the Selling Shareholders and such control persons of any Selling Shareholders, such firm
shall be designated in writing by the persons named as attorneys-in-fact for the Selling
Shareholders under the Powers of Attorney. The indemnifying party shall not be liable for any
settlement
of any proceeding effected without its written consent, but if settled with such consent or if
there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the
indemnified party from and against any loss or liability by reason of such settlement or judgment.
Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an
indemnifying party to reimburse the indemnified party for fees and expenses of counsel as
contemplated by the second and third sentences of this paragraph, the indemnifying party agrees
that it shall be liable for any settlement of any proceeding effected without its written consent
if (i)&nbsp;such settlement is entered into more than 30&nbsp;days after receipt by such indemnifying party
of the aforesaid request and (ii)&nbsp;such indemnifying party shall not have reimbursed the indemnified
party in accordance with such request prior to the date of such settlement. No indemnifying party
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 42 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">shall, without the prior written consent of the indemnified party, effect any settlement of any
pending or threatened proceeding in respect of which any indemnified party is or could have been a
party and indemnity could have been sought hereunder by such indemnified party, unless such
settlement includes an unconditional release of such indemnified party from all liability on claims
that are the subject matter of such proceeding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(e)&nbsp;</I>To the extent the indemnification provided for in Section&nbsp;11(a), 12(b) or 12(c) is
unavailable to an indemnified party or insufficient in respect of any losses, claims, damages or
liabilities referred to therein, then each indemnifying party under such paragraph, in lieu of
indemnifying such indemnified party thereunder, shall contribute to the amount paid or payable by
such indemnified party as a result of such losses, claims, damages or liabilities (i)&nbsp;in such
proportion as is appropriate to reflect the relative benefits received by the indemnifying party or
parties on the one hand and the indemnified party or parties on the other hand from the offering of
the Shares or (ii)&nbsp;if the allocation provided by Section&nbsp;11(d)(i) above is not permitted by
applicable law, in such proportion as is appropriate to reflect not only the relative benefits
referred to in Section&nbsp;11(d)(i) above but also the relative fault of the indemnifying party or
parties on the one hand and of the indemnified party or parties on the other hand in connection
with the statements or omissions that resulted in such losses, claims, damages or liabilities, as
well as any other relevant equitable considerations. The relative benefits received by the Sellers
on the one hand and the Underwriters on the other hand in connection with the offering of the
Shares shall be deemed to be in the same respective proportions as the net proceeds from the
offering of the Shares (before deducting expenses) received by each Seller and the total
underwriting discounts and commissions received by the Underwriters, in each case as set forth in
the table on the cover of the Prospectus, bear to the aggregate Public Offering Price of the
Shares. The relative fault of the Sellers on the one hand and the Underwriters on the other hand
shall be determined by reference to, among other things, whether the untrue or alleged untrue
statement of a material fact or the omission or alleged omission to state a material fact relates
to information supplied by the Sellers or by the Underwriters and the parties&#146; relative intent,
knowledge, access to information and opportunity to correct or prevent such statement or omission.
The Underwriters&#146; respective obligations to
contribute pursuant to this Section&nbsp;11 are several in proportion to the respective number of
Shares they have purchased hereunder, and not joint. The liability of each Selling Shareholder
under the contribution agreement contained in this paragraph is several and shall be limited to an
amount equal to the net proceeds received by each such Selling Shareholder under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(f)&nbsp;</I>The Sellers and the Underwriters agree that it would not be just or equitable if
contribution pursuant to this Section&nbsp;11 were determined by <I>pro rata </I>allocation (even if the
Underwriters were treated as one entity for such purpose) or by any other method of allocation that
does not take account of the equitable
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 43 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">considerations referred to in Section&nbsp;11(d). The amount
paid or payable by an indemnified party as a result of the losses, claims, damages and liabilities
referred to in Section 11(d) shall be deemed to include, subject to the limitations set forth
above, any legal or other expenses reasonably incurred by such indemnified party in connection with
investigating or defending any such action or claim. Notwithstanding the provisions of this
Section&nbsp;11, no Underwriter shall be required to contribute any amount in excess of the amount by
which the total price at which the Shares underwritten by it and distributed to the public were
offered to the public exceeds the amount of any damages that such Underwriter has otherwise been
required to pay by reason of such untrue or alleged untrue statement or omission or alleged
omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of
the Securities Act) shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation. The remedies provided for in this Section&nbsp;11 are not exclusive and
shall not limit any rights or remedies which may otherwise be available to any indemnified party at
law or in equity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(g)&nbsp;</I>The indemnity and contribution provisions contained in this Section&nbsp;11 and the
representations, warranties and other statements of the Company and the Selling Shareholders
contained in this Agreement shall remain operative and in full force and effect regardless of (i)
any termination of this Agreement, (ii)&nbsp;any investigation made by or on behalf of any Underwriter,
any person controlling any Underwriter or any affiliate of any Underwriter, any Selling Shareholder
or any person controlling any Selling Shareholder, or the Company, its officers or directors or any
person controlling the Company and (iii)&nbsp;acceptance of and payment for any of the Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.<I>&nbsp;Directed Share Program Indemnification. </I>(a)&nbsp;The Company agrees to indemnify and hold
harmless Morgan Stanley, each person, if any, who controls Morgan Stanley within the meaning of
either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act and each affiliate of
Morgan Stanley within the meaning of Rule&nbsp;405 of the Securities Act (&#147;<B>Morgan Stanley Entities</B>&#148;)
from and against any and all losses, claims, damages and liabilities (including, without
limitation, any legal or other expenses reasonably incurred in connection with defending or
investigating any such action or claim) (i)&nbsp;caused by any untrue statement or alleged untrue
statement of a material fact contained in any material prepared by or with the consent of the
Company for distribution to
Participants in connection with the Directed Share Program or caused by any omission or
alleged omission to state therein a material fact required to be stated therein or necessary to
make the statements therein not misleading; (ii)&nbsp;caused by the failure of any Participant to pay
for and accept delivery of Directed Shares that the Participant agreed to purchase; or (iii)
related to, arising out of, or in connection with the Directed Share Program, other than losses,
claims, damages or liabilities (or expenses relating thereto) that are finally judicially
determined to have resulted from the bad faith or gross negligence of Morgan Stanley Entities.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 44 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(b)&nbsp;</I>In case any proceeding (including any governmental investigation) shall be instituted
involving any Morgan Stanley Entity in respect of which indemnity may be sought pursuant to
Section&nbsp;12(a), the Morgan Stanley Entity seeking indemnity, shall promptly notify the Company in
writing and the Company, upon request of the Morgan Stanley Entity, shall retain counsel reasonably
satisfactory to the Morgan Stanley Entity to represent the Morgan Stanley Entity and any others the
Company may designate in such proceeding and shall pay the fees and disbursements of such counsel
related to such proceeding. In any such proceeding, any Morgan Stanley Entity shall have the right
to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of
such Morgan Stanley Entity unless (i)&nbsp;the Company shall have agreed to the retention of such
counsel or (ii)&nbsp;the named parties to any such proceeding (including any impleaded parties) include
both the Company and the Morgan Stanley Entity and representation of both parties by the same
counsel would be inappropriate due to actual or potential differing interests between them. The
Company shall not, in respect of the legal expenses of the Morgan Stanley Entities in connection
with any proceeding or related proceedings in the same jurisdiction, be liable for the fees and
expenses of more than one separate firm (in addition to any local counsel) for all Morgan Stanley
Entities. Any such separate firm for the Morgan Stanley Entities shall be designated in writing by
Morgan Stanley. The Company shall not be liable for any settlement of any proceeding effected
without its written consent, but if settled with such consent or if there be a final judgment for
the plaintiff, the Company agrees to indemnify the Morgan Stanley Entities from and against any
loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing
sentence, if at any time a Morgan Stanley Entity shall have requested the Company to reimburse it
for fees and expenses of counsel as contemplated by the second and third sentences of this
paragraph, the Company agrees that it shall be liable for any settlement of any proceeding effected
without its written consent if (i)&nbsp;such settlement is entered into more than 30&nbsp;days after receipt
by the Company of the aforesaid request and (ii)&nbsp;the Company shall not have reimbursed the Morgan
Stanley Entity in accordance with such request prior to the date of such settlement. The Company
shall not, without the prior written consent of Morgan Stanley, effect any settlement of any
pending or threatened proceeding in respect of which any Morgan Stanley Entity is or could have
been a party and indemnity could have been sought hereunder by such Morgan Stanley Entity, unless
such settlement includes an unconditional release of the Morgan Stanley Entities from all liability
on claims that are the subject matter of such proceeding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(c)&nbsp;</I>To the extent the indemnification provided for in Section&nbsp;12(a) is unavailable to a Morgan
Stanley Entity or insufficient in respect of any losses, claims, damages or liabilities referred to
therein, then the Company in lieu of indemnifying the Morgan Stanley Entity thereunder, shall
contribute to the amount paid or payable by the Morgan Stanley Entity as a result of such losses,
claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->- 45 -<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">relative
benefits received by the Company on the one hand and the Morgan Stanley Entities on the other hand
from the offering of the Directed Shares or (ii)&nbsp;if the allocation provided by Section&nbsp;12(c)(i)
above is not permitted by applicable law, in such proportion as is appropriate to reflect not only
the relative benefits referred to in Section&nbsp;12(c)(i) above but also the relative fault of the
Company on the one hand and of the Morgan Stanley Entities on the other hand in connection with any
statements or omissions that resulted in such losses, claims, damages or liabilities, as well as
any other relevant equitable considerations. The relative benefits received by the Company on the
one hand and the Morgan Stanley Entities on the other hand in connection with the offering of the
Directed Shares shall be deemed to be in the same respective proportions as the net proceeds from
the offering of the Directed Shares (before deducting expenses) and the total underwriting
discounts and commissions received by the Morgan Stanley Entities for the Directed Shares, bear to
the aggregate Public Offering Price of the Directed Shares. If the loss, claim, damage or
liability is caused by an untrue or alleged untrue statement of a material fact or the omission or
alleged omission to state a material fact, the relative fault of the Company on the one hand and
the Morgan Stanley Entities on the other hand shall be determined by reference to, among other
things, whether the untrue or alleged untrue statement or the omission or alleged omission relates
to information supplied by the Company or by the Morgan Stanley Entities and the parties&#146; relative
intent, knowledge, access to information and opportunity to correct or prevent such statement or
omission.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(d)&nbsp;</I>The Company and the Morgan Stanley Entities agree that it would not be just or equitable
if contribution pursuant to this Section&nbsp;12 were determined by <I>pro rata </I>allocation (even if the
Morgan Stanley Entities were treated as one entity for such purpose) or by any other method of
allocation that does not take account of the equitable considerations referred to in Section&nbsp;12(c).
The amount paid or payable by the Morgan Stanley Entities as a result of the losses, claims,
damages and liabilities referred to in the immediately preceding paragraph shall be deemed to
include, subject to the limitations set forth above, any legal or other expenses reasonably
incurred by the Morgan Stanley Entities in
connection with investigating or defending any such action or claim. Notwithstanding the
provisions of this Section&nbsp;12, no Morgan Stanley Entity shall be required to contribute any amount
in excess of the amount by which the total price at which the Directed Shares distributed to the
public were offered to the public exceeds the amount of any damages that such Morgan Stanley Entity
has otherwise been required to pay. The remedies provided for in this Section&nbsp;12 are not exclusive
and shall not limit any rights or remedies which may otherwise be available to any indemnified
party at law or in equity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(e)&nbsp;</I>The indemnity and contribution provisions contained in this Section&nbsp;13 shall remain
operative and in full force and effect regardless of (i)&nbsp;any termination of this Agreement, (ii)
any investigation made by or on behalf of any Morgan Stanley Entity or the Company, its officers or
directors or any person
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 46 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">controlling the Company and (iii)&nbsp;acceptance of and payment for any of the
Directed Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;<I>Termination</I>. The Underwriters may terminate this Agreement by notice given by you to the
Company, if after the execution and delivery of this Agreement and prior to the Closing Date (i)
trading generally shall have been suspended or materially limited on, or by, as the case may be,
any of the NYSE, the American Stock Exchange or The NASDAQ Global Market, (ii)&nbsp;trading of any
securities of the Company shall have been suspended on any exchange or in any over-the-counter
market, (iii)&nbsp;a material disruption in securities settlement, payment or clearance services in the
United States or other relevant jurisdiction shall have occurred, (iv)&nbsp;any moratorium on commercial
banking activities shall have been declared by U.S. federal, New York State, Cayman Islands, PRC or
other relevant foreign country authorities or (v)&nbsp;there shall have occurred any outbreak or
escalation of hostilities, or any change in financial markets, currency exchange rates or controls
or any calamity or crisis that, in your judgment, is material and adverse and which, singly or
together with any other event specified in this clause (v), makes it, in your judgment,
impracticable or inadvisable to proceed with the offer, sale or delivery of the Shares on the terms
and in the manner contemplated in the Time of Sale Prospectus or the Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;<I>Effectiveness; Defaulting Underwriters</I>. This Agreement shall become effective upon the
execution and delivery hereof by the parties hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, on any Closing Date, any one or more of the Underwriters shall fail or refuse to purchase
Shares that it has or they have agreed to purchase hereunder on such date, and the aggregate number
of Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to
purchase is not more than one-tenth of the aggregate number of the Shares to be purchased on such
date, the other Underwriters shall be obligated severally in the proportions that the number of
Firm Shares set forth opposite their respective names in Schedule&nbsp;II bears to the aggregate number
of Firm Shares set forth opposite the names of all such non-defaulting Underwriters, or in such
other proportions as you may specify, to purchase the Shares which such defaulting Underwriter or
Underwriters agreed
but failed or refused to purchase on such date; <I>provided </I>that in no event shall the number of
Shares that any Underwriter has agreed to purchase pursuant to this Agreement be increased pursuant
to this Section&nbsp;14 by an amount in excess of one-ninth of such number of Shares without the written
consent of such Underwriter. If, on the Closing Date, any Underwriter or Underwriters shall fail
or refuse to purchase Firm Shares and the aggregate number of Firm Shares with respect to which
such default occurs is more than one-tenth of the aggregate number of Firm Shares to be purchased
on such date, and arrangements satisfactory to you and the Company for the purchase of such Firm
Shares are not made within 36 hours after such default, this Agreement shall terminate without
liability on the part of any non-defaulting Underwriter or the Company. In any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 47 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">such case either
you or the Company shall have the right to postpone the Closing Date, but in no event for longer
than seven days, in order that the required changes, if any, in the Registration Statement, in the
Time of Sale Prospectus, in the Prospectus or in any other documents or arrangements may be
effected. If, on an Option Closing Date, any Underwriter or Underwriters shall fail or refuse to
purchase Additional Shares and the aggregate number of Additional Shares with respect to which such
default occurs is more than one-tenth of the aggregate number of Additional Shares to be purchased
on such Option Closing Date, the non-defaulting Underwriters shall have the option to (i)&nbsp;terminate
their obligation hereunder to purchase the Additional Shares to be sold on such Option Closing Date
or (ii)&nbsp;purchase not less than the number of Additional Shares that such non-defaulting
Underwriters would have been obligated to purchase in the absence of such default. Any action
taken under this paragraph shall not relieve any defaulting Underwriter from liability in respect
of any default of such Underwriter under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Agreement shall be terminated by the Underwriters, or any of them, because of any
failure or refusal on the part of any Seller to comply with the terms or to fulfill any of the
conditions of this Agreement, or if for any reason any Seller shall be unable to perform its
obligations under this Agreement, the Sellers will reimburse the Underwriters or such Underwriters
as have so terminated this Agreement with respect to themselves, severally, for all out-of-pocket
expenses (including the fees and disbursements of their counsel) reasonably incurred by such
Underwriters in connection with this Agreement or the offering contemplated hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.&nbsp;<I>Entire Agreement</I>. (a)&nbsp;This Agreement, together with any contemporaneous written
agreements and any prior written agreements (to the extent not superseded by this Agreement) that
relate to the offering of the Shares, represents the entire agreement between the Company, the
Selling Shareholders and the Underwriters with respect to the preparation of any preliminary
prospectus, the Time of Sale Prospectus, the Prospectus, the conduct of the offering, and the
purchase and sale of the Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(b)&nbsp;</I>Each of the Company and the Selling Shareholders acknowledge that in connection with the
offering of the Shares: (i)&nbsp;the Underwriters have acted
at arms length, are not agents of, and owe no fiduciary duties to, the Company, the Selling
Shareholders or any other person, (ii)&nbsp;the Underwriters owe the Company and the Selling
Shareholders only those duties and obligations set forth in this Agreement and prior written
agreements (to the extent not superseded by this Agreement), if any, and (iii)&nbsp;the Underwriters may
have interests that differ from those of the Company and the Selling Shareholders. Each of the
Company and the Selling Shareholders waive to the full extent permitted by applicable law any
claims it may have against the Underwriters arising from an alleged breach of fiduciary duty in
connection with the offering of the Shares.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 48 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.&nbsp;<I>Counterparts</I>. This Agreement may be signed in any number of counterparts, each of which
shall be an original, with the same effect as if the signatures thereto and hereto were upon the
same instrument.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.&nbsp;<I>Applicable Law</I>. (a)&nbsp;This Agreement shall be governed by and construed in accordance with
the internal laws of the State of New York.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each of the parties hereto irrevocably (i)&nbsp;agrees that any legal suit, action or
proceeding against the Company or any Selling Shareholder brought by any Underwriter or by any
person who controls any Underwriter arising out of or based upon this Agreement or the transactions
contemplated hereby may be instituted in any New York Court, (ii)&nbsp;waives, to the fullest extent it
may effectively do so, any objection which it may now or hereafter have to the laying of venue of
any such proceeding and (iii)&nbsp;submits to the exclusive jurisdiction of such courts in any such
suit, action or proceeding. Each of the Company and the Selling Shareholders irrevocably waives,
to the fullest extent permitted by law, any immunity to jurisdiction to which it may otherwise be
entitled or become entitled (including sovereign immunity, immunity to pre-judgment attachment,
post-judgment attachment and execution) in any legal suit, action or proceeding against it arising
out of or based on this Agreement or the transactions contemplated hereby which is instituted in
any New York Court or in any competent court in the Cayman Islands. Each of the Company and the
Selling Shareholders has appointed National Registered Agents, Inc., located at 875 Avenue of the
Americas, Suite&nbsp;501, New York, New York 10001, as its authorized agent (the &#147;<B>Authorized Agent</B>&#148;)
upon whom process may be served in any such action arising out of or based on this Agreement or the
transactions contemplated hereby which may be instituted in any New York Court by any Underwriter
or by any person who controls any Underwriter, expressly consents to the jurisdiction of any such
court in respect of any such action, and waives, to the fullest extent permitted by law, any other
requirements of or objections to personal jurisdiction with respect thereto. Such appointment shall
be irrevocable. Each of the Company and the Selling Shareholders represents and warrants that the
Authorized Agent has agreed to act as such agent for service of process and agrees to take any and
all action, including the filing of any and all documents and instruments, which may be necessary
to continue such appointment in full force and effect as aforesaid. Service of process upon the
Authorized Agent and written notice of such service to the Company shall be deemed, in every
respect, effective
service of process upon the Company and the Selling Shareholders as the case may be.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.&nbsp;<I>Judgment Currency</I>. In respect of any judgment or order given or made for any amount due
hereunder that is expressed and paid in a currency (the &#147;<B>judgment currency</B>&#148;) other than United
States dollars, the Company and the Selling Shareholders, as the case may be, will indemnify each
Underwriter against any loss incurred by such Underwriter as a result of any variation as between
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 49 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(i)&nbsp;the rate of exchange at which the United States dollar amount is converted into the judgment
currency for the purpose of such judgment or order and (ii)&nbsp;the rate of exchange at which an
Underwriter is able to purchase United States dollars with the amount of the judgment currency
actually received by such Underwriter. The foregoing indemnity shall constitute a separate and
independent obligation of the Company and the Selling Shareholders and shall continue in full force
and effect notwithstanding any such judgment or order as aforesaid. The term &#147;rate of exchange&#148;
shall include any premiums and costs of exchange payable in connection with the purchase of or
conversion into United States dollars.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.&nbsp;<I>Headings</I>. The headings of the sections of this Agreement have been inserted for
convenience of reference only and shall not be deemed a part of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20.&nbsp;<I>Notices</I>. All communications hereunder shall be in writing and effective only upon receipt
and if to the Underwriters shall be delivered, mailed or sent to you in care of Morgan
Stanley &#038; Co. International plc, 25 Cabot Square, Canary Wharf, London E14 4QA, United Kingdom and
J.P. Morgan Securities Inc., 383 Madison Avenue, Floor 4, New York, New York 10179; and if to the
Company shall be delivered, mailed or sent to Room&nbsp;2001-2002, 20-F, Tower A, Global Trade Center,
36 North Third Ring Road East, Dongcheng District, Beijing 100013, People&#146;s Republic of China.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;Signature pages follow.&#093;
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->- 50 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Very truly yours,<BR>
<BR>
CONCORD MEDICAL SERVICES<BR>
HOLDINGS LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;Signature Page to Underwriting Agreement&#093;
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>

<TD colspan="3" align="left"><DIV style="margin-left:20px; text-indent:-20px">The Selling Shareholders named in <BR>
Schedule&nbsp;I hereto</DIV><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Jianyu Yang&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Attorney-in-fact for and on behalf of<br>
the Selling Shareholders&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;Signature Page to Underwriting Agreement&#093;
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Accepted as of the date hereof:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Morgan Stanley &#038; Co. International plc<BR>
J.P. Morgan Securities Inc.<BR>
China International Capital Corporation Hong Kong Securities Limited

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Acting severally on behalf of themselves and<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the several Underwriters named in<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Schedule&nbsp;II hereto

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Morgan Stanley &#038; Co. International plc</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">J.P. Morgan Securities Inc.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">China International Capital Corporation</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Hong Kong Securities Limited</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;Signature Page to Underwriting Agreement&#093;
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>SCHEDULE I</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Number of</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Additional Shares</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Selling Shareholder</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>To Be Sold</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Notable Enterprise Limited</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,000,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Grand Best Group Limited</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">400,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Sino Prime Investments Limited</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">250,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ATL International Group Limited</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">150,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,800,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->I-1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>SCHEDULE II</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Number of Firm</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Shares To Be</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Underwriter</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Purchased</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Morgan Stanley &#038; Co. International plc</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">J.P. Morgan Securities Inc.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">China International Capital Corporation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Hong Kong Securities Limited</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->II-1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>SCHEDULE III</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Time of Sale Prospectus</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Preliminary Prospectus issued November&nbsp;27, 2009</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Free writing prospectus filed by the Company with the Commission on December &#091;<B>&#149;</B>&#093;, 2009</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;Other free writing prospectuses filed by the Company under Rule 433(d) of the Securities
Act&#093;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Price to public: US$&#091;<B>&#149;</B>&#093; per ADS</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->III-1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT A</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>LOCK-UP LETTER</B>
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2009
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Morgan Stanley &#038; Co. International plc<BR>
J.P. Morgan Securities Inc.<BR>
China International Capital Corporation Hong Kong Securities Limited

</DIV>

<DIV align="left" style="margin-top: 0pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="1%"></TD>

    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">c/o&nbsp;</TD>

    <TD>Morgan Stanley &#038; Co. International plc<br>
25 Cabot Square, Canary Wharf<br>
London E14 4QA<br>
United Kingdom</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Ladies and Gentlemen:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned understands that Morgan Stanley &#038; Co. International plc (&#147;<B>Morgan Stanley</B>&#148;),
J.P. Morgan Securities Inc. (<B>&#147;J.P. Morgan</B>&#148;) and China International Capital Corporation Hong Kong
(&#147;<B>CICC</B>&#148; and together with Morgan Stanley and J.P. Morgan, the &#147;<B>Representatives</B>&#148;) propose to enter
into an Underwriting Agreement (the &#147;<B>Underwriting Agreement</B>&#148;) with Concord Medical Services
Holdings Limited, an exempted company incorporated in the Cayman Islands with limited liability
(the &#147;<B>Company</B>&#148;) and certain shareholders of the Company, providing for the public offering (the
&#147;<B>Public Offering</B>&#148;) by the several underwriters listed in Schedule&nbsp;II to the Underwriting Agreement
(collectively, the &#147;<B>Underwriters</B>&#148;), of &#091;12,000,000&#093; American Depository Shares (the &#147;<B>ADSs</B>&#148;), each
ADS representing three ordinary shares of the Company at par value US$0.01 per share (the &#147;<B>Ordinary
Shares</B>&#148;), and not more than an additional &#091;1,800,000&#093; ADSs, if and to the extent that the
Representatives shall have determined to exercise the right to purchase such additional &#091;1,800,000&#093;
ADSs granted to the Underwriters pursuant to the Underwriting Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To induce the Underwriters that may participate in the Public Offering to continue their
efforts in connection with the Public Offering, the undersigned hereby agrees that, without the
prior written consent of the Representatives on behalf of the Underwriters, it will not, during the
period commencing on the date hereof and ending 180&nbsp;days after the date of the Public Offering (the
&#147;<B>Public Offering Date</B>&#148;) set forth in the final prospectus relating to the Public Offering (the
&#147;<B>Prospectus</B>&#148;), (1)&nbsp;offer, pledge, sell, contract to sell, sell any option or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Exhibit A-1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">contract to purchase, purchase any option or contract to sell, grant any option, right or
warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any
Ordinary Shares or ADSs or any securities convertible into or exercisable or exchangeable for
Ordinary Shares or ADSs or (2)&nbsp;enter into any swap or other arrangement that transfers to another,
in whole or in part, any of the economic consequences of ownership of the Ordinary Shares or ADSs,
whether any such transaction described in clause (1)&nbsp;or (2)&nbsp;above is to be settled by delivery of
Ordinary Shares, ADSs, or such other securities, in cash or otherwise. The foregoing sentence
shall not apply to (a)&nbsp;the Ordinary Shares as represented by the ADSs to be sold by the undersigned
pursuant to the Underwriting Agreement, if any, (b)&nbsp;transactions relating to Ordinary Shares, ADSs
or other securities acquired in open market transactions after the completion of the Public
Offering, <I>provided </I>that no filing under Section 16(a) of the Securities Exchange Act of 1934, as
amended (the &#147;<B>Exchange Act</B>&#148;), shall be required or shall be voluntarily made in connection with
subsequent sales of Ordinary Shares, ADSs or other securities acquired in such open market
transactions, (c)&nbsp;the exercise of any of the undersigned&#146;s rights to acquire Ordinary Shares, ADSs
or other securities of the Company issued pursuant to any share option or similar equity incentive
or compensation plan of the Company for the issuance of share options or equity grants
(collectively, &#147;<B>Equity Incentive Grants</B>&#148;), <I>provided </I>that, in each case, such plan is in effect as
of the date of and disclosed in the Prospectus (it being understood that any subsequent sale,
transfer or disposition of any securities of the Company issued upon exercise of such Equity
Incentive Grants shall be subject to the restrictions set forth in this agreement), (d)&nbsp;transfers
of Ordinary Shares or ADSs to shareholders who are existing shareholders of the Company prior to
the Public Offering (the &#147;<B>Existing Shareholders</B>&#148;) or partners, members, stockholders or affiliates
(as defined in Rule&nbsp;12b-2 of the Exchange Act) of the Existing Shareholders, (e)&nbsp;transfers of
Ordinary Shares, ADSs or any security convertible into Ordinary Shares or ADSs (i)&nbsp;to an immediate
family member or a trust formed for the benefit of an immediate family member, (ii)&nbsp;as a bona fide
gift or (iii)&nbsp;through will or intestacy, (f)&nbsp;transfers or distributions of Ordinary Shares, ADSs or
any security convertible into Ordinary Shares or ADSs to partners, members, stockholders or
affiliates of the undersigned, <I>provided </I>that in the case of any transfer or distribution pursuant
to clauses (d), (e)&nbsp;or (f), (x)&nbsp;each transferee, donee or distributee shall sign and deliver a
lock-up letter substantially in the form of this agreement and (y)&nbsp;no filing under Section 16(a) of
the Exchange Act reporting a reduction in beneficial ownership of Ordinary Shares or ADSs, shall be
required or shall be voluntarily made during the restricted period referred to in the foregoing
sentence, or (g)&nbsp;the establishment of a trading plan pursuant to Rule&nbsp;10b5-1 under the Exchange Act
for the transfer of Ordinary Shares or ADSs, <I>provided </I>that such plan does not provide for the
transfer of Ordinary Shares or ADSs during the restricted period. In addition, the undersigned
agrees that, without the prior written consent of the Representatives on behalf of the
Underwriters, it will not, during the period commencing on the
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->Exhibit A-2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">date hereof and ending 180&nbsp;days after the Public Offering Date, make any demand for or
exercise any right with respect to, the registration of any Ordinary Shares, ADSs or any security
convertible into or exercisable or exchangeable for Ordinary Shares or ADSs. The undersigned also
agrees and consents to the entry of stop transfer instructions with the Company&#146;s transfer agent
and registrar against the transfer of the undersigned&#146;s Ordinary Shares or ADSs except in
compliance with the foregoing restrictions. For purposes of this paragraph, &#147;immediate family&#148;
means the spouse, domestic partner, lineal descendants, father, mother, brother or sister of the
transferor.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;during the last 17&nbsp;days of the restricted period the Company issues an earnings release or
material news or a material event relating to the Company occurs; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;prior to the expiration of the restricted period, the Company announces that it will
release earnings results during the 16-day period beginning on the last day of the restricted
period;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the restrictions imposed by this agreement shall continue to apply until the expiration of the
18-day period beginning on the issuance of the earnings release or the occurrence of the material
news or material event, unless the Representatives waive, in writing, such extension.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned shall not engage in any transaction that may be restricted by this agreement
during the 34-day period beginning on the last day of the initial restricted period unless the
undersigned requests and receives prior written confirmation from the Company or the
Representatives that the restrictions imposed by this agreement have expired.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned understands that the Company and the Underwriters are relying upon this
agreement in proceeding toward consummation of the Public Offering. The undersigned further
understands that this agreement is irrevocable and shall be binding upon the undersigned&#146;s heirs,
legal representatives, successors and assigns.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->Exhibit A-3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whether or not the Public Offering actually occurs depends on a number of factors, including
market conditions. Any Public Offering will only be made pursuant to an Underwriting Agreement,
the terms of which are subject to negotiation between the Company and the Underwriters.
Notwithstanding anything to the contrary contained herein, this agreement will terminate and the
undersigned will be released from all of its obligations hereunder on March&nbsp;31, 2010 if the Public
Offering Date shall not have occurred on or before such date.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Very truly yours,</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR><TD align="left" valign="top">&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
(Name)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR><TD align="left" valign="top">&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
(Address)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->Exhibit A-4<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
